CA2086258C - Pasteurella multocida toxoid vaccines - Google Patents
Pasteurella multocida toxoid vaccines Download PDFInfo
- Publication number
- CA2086258C CA2086258C CA002086258A CA2086258A CA2086258C CA 2086258 C CA2086258 C CA 2086258C CA 002086258 A CA002086258 A CA 002086258A CA 2086258 A CA2086258 A CA 2086258A CA 2086258 C CA2086258 C CA 2086258C
- Authority
- CA
- Canada
- Prior art keywords
- toxoid
- pasteurella multocida
- vaccine composition
- bacterin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000606856 Pasteurella multocida Species 0.000 title claims abstract description 128
- 229940051027 pasteurella multocida Drugs 0.000 title claims abstract description 36
- 229940031572 toxoid vaccine Drugs 0.000 title description 13
- 229960005486 vaccine Drugs 0.000 claims abstract description 148
- 239000000203 mixture Substances 0.000 claims abstract description 82
- 241001465754 Metazoa Species 0.000 claims abstract description 51
- 231100000033 toxigenic Toxicity 0.000 claims abstract description 13
- 230000001551 toxigenic effect Effects 0.000 claims abstract description 13
- 239000003053 toxin Substances 0.000 claims description 50
- 231100000765 toxin Toxicity 0.000 claims description 50
- 230000002163 immunogen Effects 0.000 claims description 34
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 26
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 101710110818 Dermonecrotic toxin Proteins 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 5
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims description 2
- 230000003698 anagen phase Effects 0.000 claims 4
- 229940087586 escherichia coli antigen Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 241000282887 Suidae Species 0.000 description 110
- 108700012359 toxins Proteins 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 32
- 241000282898 Sus scrofa Species 0.000 description 27
- 238000002255 vaccination Methods 0.000 description 21
- 230000001147 anti-toxic effect Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 244000309725 Pasteurella multocida type A Species 0.000 description 17
- 229940001442 combination vaccine Drugs 0.000 description 17
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 15
- 206010039088 Rhinitis atrophic Diseases 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 210000004894 snout Anatomy 0.000 description 12
- 206010003694 Atrophy Diseases 0.000 description 10
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 10
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 10
- 230000037444 atrophy Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000021017 Weight Gain Diseases 0.000 description 9
- 210000003022 colostrum Anatomy 0.000 description 9
- 235000021277 colostrum Nutrition 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 241000588807 Bordetella Species 0.000 description 8
- 238000003307 slaughter Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 201000000297 Erysipelas Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 7
- 241000186811 Erysipelothrix Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940033663 thimerosal Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229910001679 gibbsite Inorganic materials 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960000380 propiolactone Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 101710186708 Agglutinin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000032537 response to toxin Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010052122 Dellen Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000143973 Libytheinae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 101000762952 Pasteurella multocida Dermonecrotic toxin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
This invention provides vaccine compositions, methods of producing same and methods for protecting porcine animals against disease associated with infection by toxigenic Pasteurella multocida.
The vaccines of this invention contain effective amounts of a free, soluble P. multocida toxoid and/or a P. multocida bacterin with a cellbound toxoid.
The vaccines of this invention contain effective amounts of a free, soluble P. multocida toxoid and/or a P. multocida bacterin with a cellbound toxoid.
Description
PASTEURELLA MULTOCIDA TOXOID VACCINES
Field of the Invention This invention is generally in the field of veterinary vaccines, vaccine compositions, and methods of producing same. More particularly, this invention relates to vaccine compositions and methods for protecting animals against diseases associated with infection by toxigenic strains of Pasteurella multocida.
Background of the Invention Pasteurella multocida has been associated with disease in many species of animals, including man and bovine, ovine and porcine animals. It typically affects the nasopharyngeal regions and lungs of infected animals.
For example, toxigenic strains of P. multocida, capsular type A or D, cause atrophic rhinitis in swine. Atrophic rhinitis (AR) results in severe necrosis of the epithelia of the upper respiratory tract as well as deformities and atrophy of the turbinates and snouts of pigs.
The pathogenicity of P. multocida is due in large part to the production of a potent necrotizing toxin, also called dermonecrotic toxin (DNT), which will be referred to hereinafter as "the toxin". The toxin has been characterized as a heat-labile protein with a molecular weight of approximately 140,000 to 160,000.
P. multocida is distinguishable from other species of Pasteurella on the basis of its growth characteristics, as follows: hemolysis: negative (90%);
growth on MacConkey's agar: negative; indole production:
positive; urease production: negative; and mannitol metabolism: positive. See, Zinsser, Microbiology, edit.
by Joklik et al., Appleton-Century-Crofts, New York, 1980, pages 791-793.
Currently available vaccines for protecting animals from diseases associated with infection by P.
multocida include inactivated toxigenic P. multocida cells, inactivated preparations of partly purified P.
multocida toxin and combinations of P. multocida cell-free preparations with other inactivated P. multocida strains or B. bronchiseptica strains. [See, e.g., M.
Kobisch et al, Vet. Record, 124:57-61 (1989); and N. T.
Foged et al, Vet. Record, 125:7-11 (1989)]. These vaccine preparations, however, are not fully protective against disease because they fail to elicit effective amounts of the antibody that neutralizes the toxin, known as "antitoxin".
?
4~.i,.~U
Field of the Invention This invention is generally in the field of veterinary vaccines, vaccine compositions, and methods of producing same. More particularly, this invention relates to vaccine compositions and methods for protecting animals against diseases associated with infection by toxigenic strains of Pasteurella multocida.
Background of the Invention Pasteurella multocida has been associated with disease in many species of animals, including man and bovine, ovine and porcine animals. It typically affects the nasopharyngeal regions and lungs of infected animals.
For example, toxigenic strains of P. multocida, capsular type A or D, cause atrophic rhinitis in swine. Atrophic rhinitis (AR) results in severe necrosis of the epithelia of the upper respiratory tract as well as deformities and atrophy of the turbinates and snouts of pigs.
The pathogenicity of P. multocida is due in large part to the production of a potent necrotizing toxin, also called dermonecrotic toxin (DNT), which will be referred to hereinafter as "the toxin". The toxin has been characterized as a heat-labile protein with a molecular weight of approximately 140,000 to 160,000.
P. multocida is distinguishable from other species of Pasteurella on the basis of its growth characteristics, as follows: hemolysis: negative (90%);
growth on MacConkey's agar: negative; indole production:
positive; urease production: negative; and mannitol metabolism: positive. See, Zinsser, Microbiology, edit.
by Joklik et al., Appleton-Century-Crofts, New York, 1980, pages 791-793.
Currently available vaccines for protecting animals from diseases associated with infection by P.
multocida include inactivated toxigenic P. multocida cells, inactivated preparations of partly purified P.
multocida toxin and combinations of P. multocida cell-free preparations with other inactivated P. multocida strains or B. bronchiseptica strains. [See, e.g., M.
Kobisch et al, Vet. Record, 124:57-61 (1989); and N. T.
Foged et al, Vet. Record, 125:7-11 (1989)]. These vaccine preparations, however, are not fully protective against disease because they fail to elicit effective amounts of the antibody that neutralizes the toxin, known as "antitoxin".
?
4~.i,.~U
There remains a need in the art of veterinary practice for effective vaccines against infection of animals by toxigenic P. multocida.
Summary of the Invention The present invention provides novel vaccine compositions and components which protect animals against disease associated with infection by toxigenic Pasteurella multocida. These vaccine compositions are characterized by the ability to elicit significant quantities of circulating antitoxin.
In a first aspect, this invention provides a vaccine which comprises an immunogenic amount of a stable, soluble, cell-free toxoid of P. multocida, and a carrier suitable for internal administration. This novel P. multocida toxoid is produced by a method including a step of subjecting the toxin to varying pH and temperature, which method is also a novel aspect of the present invention. The terin "toxoid" describes a preparation of the toxin that has been inactivated ("toxoided") by a process that abolishes its toxicity without destroying its ability to induce the production of the specific neutralizing antitoxin.
WO 91/19419 PG'I'/US91/04W2 In another aspect, the invention provides a novel vaccine composition containing an immunogenic amount of a whole Pasteurella multocida bacterin with cell-bound toxoid. This composition can induce in a previously unvaccinated animal a superior antitoxin response compared to the free, soluble toxoid. This composition is also preferably associated with a carrier suitable for internal administration.
In still another aspect, the invention provides a novel vaccine composition comprising immunogenic amounts of (1) a whole Pasteurella multocida bacterin with cell-bound toxoid which, upon internal administration to an animal, induces an antitoxin response, and (2) the free toxoid of P. multocida. This vaccine composition produces an unexpected synergistic antitoxin response, much greater than the sum of the separate effects of the two components. A carrier is also desirably associated with this composition.
In a further aspect the above three vaccine compositions may be varied by combination with an immunogenic amount of one or more additional antigens.
Such additional antigens may include, among others, a B.
bronchiseptica bacterin or an Erysilpelothrix rhusiopathiae bacterin. Other conventional vaccine components may also be added to the vaccine compositions of this invention.
203+.~~258 Another aspect of this invention includes a vaccine dosage unit of each of the above vaccine compositions. One embodiment of the invention includes a vaccine dosage unit comprising 0.5 to 3 mL of a sterile 5 solution containing an immunogenic amount of between about 80 to about 1000 relative toxoid units (RU) of a multocida toxoid. Another embodiment includes a dosage unit of 0.5 to 3 mL of a sterile suspension of an immunogenic amount of between 0.5 to 8 optical density units (OD) measured at 625 nm of a P. multocida bacterin with cell-bound toxoid which upon internal administration to an animal induces an antitoxin response. Still another embodiment is a dosage unit comprising 0.5 to 3 mL of a sterile mixture of the free and cell-bound toxoids. A further embodiment is a dosage unit comprising 0.5 to 3 mL of a sterile mixture of immunogenic amounts of the free and cell-bound toxoids and one or more additional antigenic components.
In yet another aspect, the invention provides a method for detoxifying the P. multocida toxin to prepare a free, soluble immunogenic toxoid which comprises incubating the toxin at a pH greater than 9 for at least 12 hours.
A furtheraspect of the invention provides a method for detoxifying a whole P. multocida culture in which the toxin is completely converted to a stable toxoid within the bacterial cells, for use as a vaccine.
WO 91/19419 PC,'I'/US91/04002 VgMb This method involves treating the culture with a suitable concentration of formaldehyde, at a suitable temperature and for a sufficient time.
Yet a further aspect of this invention is a method for vaccina-ting an animal against P. multocida which comprises internally administering to the animal an effective amount of one or more of the vaccine compositions descxibed above.
Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments thereof.
Detailed Description of the Invention The present invention provides vaccine compositions useful in the prophylaxis of diseases resulting from infections with toxigenic P. multocida, non-toxigenic strains of P. multocida, and other pathogenic organisms. Such diseases include atrophic rhinitis (AR), pleuritic and pneumonic pasteurellosis, and erysipelas, among others.
One embodiment of this invention is a vaccine which comprises an immunogenic amount of a free, soluble P. multocida toxoid in a suitable carrier. The toxoid of this invention is prepared generally by extracting toxin from the bacterial-eells and causing a partial denaturation by incubating the cell-free toxin for about WO 91/19419 PC,'T/US91/04092 F:' ~I (J :l J t,~i ~
Summary of the Invention The present invention provides novel vaccine compositions and components which protect animals against disease associated with infection by toxigenic Pasteurella multocida. These vaccine compositions are characterized by the ability to elicit significant quantities of circulating antitoxin.
In a first aspect, this invention provides a vaccine which comprises an immunogenic amount of a stable, soluble, cell-free toxoid of P. multocida, and a carrier suitable for internal administration. This novel P. multocida toxoid is produced by a method including a step of subjecting the toxin to varying pH and temperature, which method is also a novel aspect of the present invention. The terin "toxoid" describes a preparation of the toxin that has been inactivated ("toxoided") by a process that abolishes its toxicity without destroying its ability to induce the production of the specific neutralizing antitoxin.
WO 91/19419 PG'I'/US91/04W2 In another aspect, the invention provides a novel vaccine composition containing an immunogenic amount of a whole Pasteurella multocida bacterin with cell-bound toxoid. This composition can induce in a previously unvaccinated animal a superior antitoxin response compared to the free, soluble toxoid. This composition is also preferably associated with a carrier suitable for internal administration.
In still another aspect, the invention provides a novel vaccine composition comprising immunogenic amounts of (1) a whole Pasteurella multocida bacterin with cell-bound toxoid which, upon internal administration to an animal, induces an antitoxin response, and (2) the free toxoid of P. multocida. This vaccine composition produces an unexpected synergistic antitoxin response, much greater than the sum of the separate effects of the two components. A carrier is also desirably associated with this composition.
In a further aspect the above three vaccine compositions may be varied by combination with an immunogenic amount of one or more additional antigens.
Such additional antigens may include, among others, a B.
bronchiseptica bacterin or an Erysilpelothrix rhusiopathiae bacterin. Other conventional vaccine components may also be added to the vaccine compositions of this invention.
203+.~~258 Another aspect of this invention includes a vaccine dosage unit of each of the above vaccine compositions. One embodiment of the invention includes a vaccine dosage unit comprising 0.5 to 3 mL of a sterile 5 solution containing an immunogenic amount of between about 80 to about 1000 relative toxoid units (RU) of a multocida toxoid. Another embodiment includes a dosage unit of 0.5 to 3 mL of a sterile suspension of an immunogenic amount of between 0.5 to 8 optical density units (OD) measured at 625 nm of a P. multocida bacterin with cell-bound toxoid which upon internal administration to an animal induces an antitoxin response. Still another embodiment is a dosage unit comprising 0.5 to 3 mL of a sterile mixture of the free and cell-bound toxoids. A further embodiment is a dosage unit comprising 0.5 to 3 mL of a sterile mixture of immunogenic amounts of the free and cell-bound toxoids and one or more additional antigenic components.
In yet another aspect, the invention provides a method for detoxifying the P. multocida toxin to prepare a free, soluble immunogenic toxoid which comprises incubating the toxin at a pH greater than 9 for at least 12 hours.
A furtheraspect of the invention provides a method for detoxifying a whole P. multocida culture in which the toxin is completely converted to a stable toxoid within the bacterial cells, for use as a vaccine.
WO 91/19419 PC,'I'/US91/04002 VgMb This method involves treating the culture with a suitable concentration of formaldehyde, at a suitable temperature and for a sufficient time.
Yet a further aspect of this invention is a method for vaccina-ting an animal against P. multocida which comprises internally administering to the animal an effective amount of one or more of the vaccine compositions descxibed above.
Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments thereof.
Detailed Description of the Invention The present invention provides vaccine compositions useful in the prophylaxis of diseases resulting from infections with toxigenic P. multocida, non-toxigenic strains of P. multocida, and other pathogenic organisms. Such diseases include atrophic rhinitis (AR), pleuritic and pneumonic pasteurellosis, and erysipelas, among others.
One embodiment of this invention is a vaccine which comprises an immunogenic amount of a free, soluble P. multocida toxoid in a suitable carrier. The toxoid of this invention is prepared generally by extracting toxin from the bacterial-eells and causing a partial denaturation by incubating the cell-free toxin for about WO 91/19419 PC,'T/US91/04092 F:' ~I (J :l J t,~i ~
12 to 24 hours at a pH greater than 9, at an incubation temperature of between about 12 C to about 19 C.
More specifically, the free toxoid of this invention is prepared as follows: A selected toxigenic P. multocida strain is grown in a suitable culture medium. At the end of the growth cycle, the toxin is liberated from the cells by conventional physical or chemical means e.g., french press or sonic disruption, and cellular debris is removed by centrifugation and filtration. The cell-free extracted toxin is then incubated, preferably at pH of about 10.5, at ambient or slightly cooler temperature for preferably 18 hours.
Following this incubation, the pH is adjusted to neutrality. This process results in complete detoxification of the toxin, providing a toxoid soluble in aqueous solutions (e.g. phosphate buffered saline, tris buffered saline).
The soluble P. multocida toxoid preparation of this invention is both antigenic and immunogenic.
Specifically, the soluble toxoid can elicit antibodies that can bind to the toxin, and neutralize its toxicity.
Further, the soluble toxoid of this invention is characteristically stable at 4 C for at least 24 months, which is a highly advantageous commercial characteristic, indicating that this vacc-ine may be stored for later use.
2 :~~~2 5V 8 8 As another embodiment of this invention there is provided a whole bacterin-toxoid of P. multocida which contains the toxoid encapsulated and stabilized within the bacterial cell. The bacterin toxoid is prepared from a culture that is still growing exponentially and that has not yet begun to release the toxin into the growth medium. Formalin (formaldelhyde solution USP) is added at a concentration of 0.5% v/v and inactivation is continued at about 37 C for 4 days. Other formalin concentrations may be employed in this method. However a higher concentration will require a shorter inactivating incubation period, and a lower concentration will require a longer inactivating incubation period. One of $kill in the art can readily determine these parameters based on this disclosure. The toxoid is thereby encapsulated within the bacterial cell. The dead bacterial cells, with the toxoid sequestered safely within, are ideal antigenic particles for presentation to those host cells that mediate the immunizing process. This is especially important for animals that have not previously been exposed to the toxin or the toxoid and that totally lack antitoxin.
In the P. multocida bacterin-toxoid of this invention the cell-bound toxoid is remarkably stable.
Loss of antigenic potency was undetectable after storage at 4 C for more than two years.
9 .~ 1 v For purposes of this invention, any toxigenic strain of P. multocida may be used to provide the free toxoid or the bacterin-toxoid of this invention. The free or cell-bound toxoids described above can be derived from any strain of P. multocida which elaborates dermonecrotic toxin. Several such strains are available, e.g., from the American Type Culture Collection, Rockville, Maryland or from a variety of veterinary colleges or laboratories. The strain used below in the examples is P. multocida, type D, strain 8, which is available, upon request, from the University of Illinois.
Suitable culture media for use in growing the P. multocida cultures may be selected by one of skill in the art, but preferably includes, without limitation, the medium described by Herriott et al, "Defined Medium for Growth of Hemophilus Influenzae", J. Bact., 101:'513-516 (1970).
The above described novel free toxoid and whole bacterin-toxoid may be employed separately in vaccine compositions for induction of an antitoxin response that will prevent the pathological changes characteristic of atrophic rhinitis caused by toxigenic P. multocida. In a vaccine composition, an immunogenic amount of.the free toxoid or the bacterin-toxoid is desirably mixed with -'~ r suitable conventional vaccine adjuvants and physiologic vehicles for injection into mammals, especially swine.
A more preferred vaccine composition is provided by a synergistic combination of the free toxoid 5 and the whole bacterin-toxoid described above. The combination vaccine of this invention combines the whole bacterin-toxoid with the soluble toxoid, both vaccine components prepared as described above. No other toxoids or vaccines are prepared in this manner. Such a 10 combination vaccine is prepared by mixing an immunogenic amount of free toxoid and an immunogenic amount of bacterin-toxoid with suitable adjuvants and physiologic vehicles for injection into mammals. Preferred.adjuvants include amphigen and aluminum hydroxide gel.
In vaccination experiments with animals, as reported below in Examples 8 and 10, these two vaccine components have been found to act synergistically in a single vaccine preparation. The "combination vaccine"
produces in the vaccinated animal a surprisingly greater effect than that expected by simply adding the effects of each toxoid component administered separately. This combination vaccine stimulates a remarkable production of antitoxin in tested animals. This combined effect can also be generated by sequentially administering the bacterin-toxoid vaccine,-followed by an injection of the soluble toxoid vaccine.
2 '13; 8 6 29, 8 While not wishing to be bound by theory, it is presently believed that the bacterin-toxoid vaccine primes the animals, particularly immunologically naive animals incapable of responding to soluble toxoid. A
second dose of the bacterin-bound toxoid induces a moderate secondary response. Once primed by the toxoid-rich cells of the bacterin-toxoid, however, the anima].s are very responsive to the soluble free toxoid. Just as the bacterin-toxoid is a superior priming agent, the soluble toxoid has been observed to be a superior booster.
Still other preferred vaccine compositions of this invention result from combining the free toxoid and/or the bacterin-toxoid of this invention with other vaccinal agents. An illustrative example is a vaccine composition formed by the combination of a whole cell B.
bronchiseptica bacterin with the P. multocida bacterin-toxoid. Alternatively, the P. multocida bacterin-toxoid is illustrated in further combination with E.
rhusionathiae. Other possible vaccinal agents which may be combined with the vaccine components of this invention include, without limitation, Escherichia coli, Streptococcus suis, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Clostridium perfrinaens types C and D toxoids, Pseudorabies Virus Vaccine (modified live virus and/or killed virus), Rotavirus Vaccine (modified live virus), Coronavirus Vaccine (modified live virus).
Vaccines of the invention may be prepared as pharmaceutical compositions containing an effective immunogenic amount of the free toxoid and/or the whole bacterin-toxoid, as active ingredients in a nontoxic and sterile pharmaceutically acceptable carrier. A preferred embodiment of the vaccine of the invention is composed of an aqueous suspension or solution containing the free toxoid and/or bacterin-toxoid, preferably buffered at physiological pH, in a form ready for injection.
Alternatively or additionally, the free toxoid and/or bacterin-toxoid can be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response. Such adjuvants include, among others, amphigen, aluminum hydroxide, muramyl dipeptide, and saponins such as Quil A.
In yet another exemplary alternative, the free toxoid and/or bacterin-toxoid can be administered with another immunostimulating preparation, such as B.
bronchiseptica or E. rhusiopathiae bacterins prepared by known techniques.
* Trademark For purposes of this invention an immunogenic amount of free soluble toxoid, when administered as the sole active ingredient, may be defined in terms of relative toxoid units ("RU"). The value of RU was determined empirically based on an estimate of the amount of toxoid which, when inoculated into mice, would elicit an immune response that protected mice against the lethal effects of intraperitoneal inoculation of approximately 30 LDso of purified toxin. In this system, an antigen extinction study was performed and a PD$o determined. A
PD50, which is a calculated value, is defined as the amount of toxoid required to protect 50 percent of the mice from challenge with a defined amount of toxin, in this instance, 30 LD50 of purified toxin. Thus one RU is approximately equal to one mouse PD50. Thus, a range of immunogenic amounts of free soluble toxoid is between about 50 to about 1000 RU. More preferably the immunogenic amount ranges between about 50 to about 650 RU. Another preferred range is between about 80 to about 450 RU. Still another preferred range is between about 80 to about 150 RU. Another.immunogenic amount of the free toxoid, as defined by weight, ranges between about 16.2 and about 32.4 g toxoid.
WO 91/19419 P('I'/US91/04092 208 16 2r)0 For purposes of this invention an immunogenic amount of bacterin-toxoid, when injected as the sole active ingredient, is defined as an optical density (O.D.) of between about 0.5 and about 8 per ml, more desirably, about 1 to about 4 per ml. Still another preferred range is an O.D. of between 1 to about 3 per ml. As used throughout this specification, the terms O.D., optical unit (OU) or absorbency unit are interchangeable and are measured at 625 nm in a Spectronic 20 spectrophotometer unless otherwise specified.
In a vaccine composition containing both components, the same immunogenic amounts may be employed.
Alternatively, due to the synergy of the components when combined, the immunogenic amount of the free soluble toxoid may range between about 100 and about 150 RU and, more preferably between about 100 to about 120 RU. The immunogenic, amount of the bacterin-toxoid in combination with the free toxoid may be in the lower O.D. ranges, from about 1 to about 3, and more preferably, about 2.
In such a combination vaccine, the bacterin-toxoid may be reduced to approximately 1.875.O.D. or absorbency units.
Other appropriate therapeutically effective doses can be determined readily by those of skill in the art based on the above immunogenic amounts, the condition being treated and the physiological characteristics of the animal. It is preferred that the vaccine of the invention, when in a pharmaceutical preparation, be present in unit dosage forms. Accordingly, a pharmaceutical preparation provides a unit dosage of 5 between 0.5 to 3 mis of a sterile preparation containing an immunogenic amount of the active ingredients, whether the active ingredient is the free toxoid only, the cell-bound bacterin-toxoid only, or a combination thereof. In the presence of additional active agents, these unit 10 dosages can be readily adjusted by those of skill in the art.
The presently preferred formulation, which appears to give maximum synergy is a Bordetella bronchiseptica, Erysipelothrix rhusiopathiae, Pasteurella 15 multocida bacterin toxoid combination which contains approximately 100 RU free toxoid with approximately 1.875 absorbency units cell-bound toxoid.
A desirable dosage regimen involves administration of two doses of desired vaccine composition, where the antigenic content (i.e., immunogenic amount) of each fraction is desirably as stated above. The mode of administration of the vaccines of the invention may be any suitable route which delivers the vapcine to the host. However, the vaccine is preferably administered s-ubcutaneously or by intramuscular injection. Other modes of administration may also be employed, where desired, such as intradermally or intravenously.
Present investigations with swine employ intramuscular injection of two doses of vaccine administered to the subject animal at least two weeks apart. These studies have shown that, for each of the above described vaccine compositions, a primary immunization of newborn animals is desirably initiated at about one week of age with a booster dose at weaning age.
For primary immunization of pregnant dams, two doses are recommended with the last dose administered two weeks before farrowing. A booster dose is recommended prior to each subsequent farrowing. Semi-annual revaccination is recommended for boars.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, general health, sex, and diet of the patient; the species of the patient; the time of administration; the route of administration; synergistic effects with any other drugs being administered; and the degree of protection being sought. Of course, the administration can be repeated at suitable intervals if necessary or desirable.
WO 91/19419 PC'T/US91/04092 ~tl 8 6 2J8 The specific mechanism of protection induced by the vaccine compositions of the present invention is the induction of toxin-neutralizing antibody (antitoxin) in vaccinated animals, as indicated by the in vivo animal tests described below.
The examples which follow illustrate preferred methods for preparing the free soluble toxoid and bacterin-toxoid of the invention and for preparing and testing a variety of vaccines containing these novel components. These examples are illustrative only and do not limit the scope of the present invention.
A. Culturina the P. multocida P. multocida type D (strain 8) [Dr. Ross Cowart, University of Illinois, Urbana, Illinois) is subcultured in a modified chemically defined synthetic medium for one day. The medium is described by Herriott et al, J. Bact., 101:513-516 (1970).
The pH of the assembled medium is adjusted to 7.3 + 0.2 with sterile NaOH. Cells from this culture are transferred to fresh synthetic medium and this culture, when grown, is combined with a cryopreservative and stored at -70 C. Production cultures are grown to harvest during incubation at approximately 36 1 C for WO 91 / 19419 PC'!'/US91 /04092 between 3 and 24 hours following inoculation. The dissolved oxygen content of the culture is maintained by aeration with sterile air and by agitation. Sterile antifoam solution is used to control foam. The pH of the culture is maintained at 7:3 0.2.
At the end of the growth cycle, multocida cultures are examined and cell density is determined by absorbance at 650 nm. Agitation is then decreased, and aeration and pH control are discontinued.
The toxin content of the lysate is measured by mouse lethality (LD50) and by the Enzyme-linked Immunosorbent.Assay (ELISA) described below in Example 4.
B. Pre-detoxification treatment Following growth of the organism, sterile merthiolate is added to the culture in an amount less than or equal to 0.01 percent weight per volume. Culture fluids may be aseptically transferred through closed connections to a sterile closed container. The container is connected through closed fittings to an apparatus used to physically lyse cells and release cellular contents, e.g., a "GAULIN" model l5M laboratory homogenizer.
Bacterial cells in the culture fluid are lysed by continuous passage through the pressure chamber of the homogenizer. This subjects the cells to an immediate pressure drop from between an initial pressure 19 ru (,~vl3i7n~~J
of between 2000 and 5000 psi to ambient pressure of 15 psi. The lysed cells are aseptically deposited into another closed container.
The lysate is clarified by sequential steps of centrifugation and/or microporous filtration.
Clarified solutions may be concentrated before or after filter sterilization. Ethylenediaminetetraacetic acid (EDTA), in an amount up to a final concentration of 5 mM, and glycerol, in an amount up to a final concentration of 1.0% (vol/vol), are added before concentrating and filter-sterilizing, to prevent aggregation of the concentrated proteins.
C. Detoxification Sterile 5 N NaOH is slowly and aseptically added to sterile toxin to increase the pH to approximately 10.55 0.10 pH units. At this pH, the detoxification occurs as the mixture is allowed to stir slowly at approximately 15 1 C for.between 15 and 24 hours. The pH is not adjusted thereafter until detoxification is complete or aliquots are taken to measure residual toxicity. Sterile 5 N HC1 is then slowly and aseptically added to adjust the pH to 6.80 +
0.20 pH units.
WO 91/19419 PCT/US91/0401%2 2 0 8 6>5 8 20 At two-hour intervals beginning 16 hours after the pH is adjusted to 10.55, an aliquot is taken.
Residual toxicity of each aliquot is measured and expressed in mouse LD50's per mL. A preparation with an initial value of nearly 10,000 LDso's per mL is usually detoxified 18 hours after adjusting the pH to 10.55, without appreciable decrease in assayable antigen content. Thereafter the pH is adjusted to 6.80 + 0.1 unit with 5N HC1. The toxoid is then stored at 2 to 7 C
until combined with other components and assembled into vaccine compositions. If the injection of mice shows any residual toxicity, the pH of the preparation is again raised to 10.55, and the temperature to 15 C. After several hours, depending on the degree of toxicity detected, the preparation is neutralized, cooled, stored, and tested once more.
An illustrative toxoid vaccine formulation according to the invention was made by preparing the soluble free toxoid as described above in Example 1.
The buffer used to prepare the vaccine compositions is sterile saline at a neutral pH. Sterile aluminum hydroxide gel is used as adjuvant and added at a level sufficient to adsorb toxoid, generally 12% 1%
(vol/vol). The vaccine compositions are prepared by thoroughly mixing, then dispensing the indicated amount of toxoid and aluminum hydroxide gel into a 500 ml beaker. Sterile saline is then added. This mixture is stirred and stored at 4 C. Dosage amounts of 2 ml/dose are desirable, which provides about 450 relative toxoid units per dose.
Table I illustrates the formulation of two free-toxoid vaccines according to the invention.
Table I
Experimental Lot Component Total Volume A Toxoid Concentrate 150.0 ml Aluminum Hydroxide Gel 36.0 ml Sterile Saline 114.0 ml Total 300.0 ml B Toxoid Concentrate 235.0 ml Aluminum Hydroxide Gel 41.0 ml Sterile Saline 304.0 ml Total 580.0 ml These free-toxoid vaccine formulations are useful as an aid in prevention of atrophic rhinitis in swine caused by P. multocida infections. An exemplary test of the free toxoid vaccine is performed by injecting the formulations into swine (pigs and dams) as described below.
2~~8 6 2 Using the formulations of Example vaccinations were administered intramuscularly to pigs and dams selected at random according to the following protocols. In each test after vaccination the animals were challenged with purified toxin at a dose known to consistently induce clinical signs of atrophic rhinitis in pigs. Toxicity of DNT was evaluated in mice before and after challenge. The total dose of toxin each pig received was 8.4 g, or 50 mouse LD50. Toxin was administered in three equal doses over a three day period beginning approximately two weeks following vaccination.
Results of the challenge were evaluated approximately 28 days following the first dose of toxin.
The percent weight gain was calculated by the number of pounds gained in the 28 days following challenge divided by the weight, in pounds, at challenge. Nasal turbinate atrophy was evaluated by cross-section of the snout at the first premolar tooth as follows: score 0, normal;
score 1, minimal atrophy; score 2, moderate atrophy;
score 3, substantial atrophy; score 4, near complete atrophy; and score 5, complete atrophy.
Protocol I: Four gilts were vaccinated with a 2 ml dose of P. multocida free toxoid (A), described above in Example 2. Two-gilts failed to farrow because of an infection of porcine parvovirus and were removed from the facility as soon as disease was evident. Pigs born of the two remaining gilts were vaccinated at 13 days of age (gilt 637, 7 pigs) and 9 days of age (gilt 638, 4 pigs) with a 2 ml dose of P. multocida free toxoid (B), described in Example 2. Second vaccinations were administered to all pigs two weeks later. Pigs were challenged with a dose of toxin two weeks following the second vaccination. Gilts from the same herd with farrowing dates similar to vaccinated gilts provided contemporary unvaccinated control pigs.
Following challenge, vaccinated and unvaccinated control pigs were commingled until they were slaughtered for final scoring. Table II illustrates the effects of challenge on pigs which were farrowed from dams vaccinated with two doses of vaccine A, and which were themselves vaccinated (VX) with two doses of free toxoid vaccine 5, compared to unvaccinated (NonVX) animals. These results show significantly lower snout scores and significantly better weight gains in the vaccinated group.
Table II
Weight at Weight at Weight Weight Mean Group No. Challenge Slaughter Gain Gain Snout (lb) % Score VX 10 26.20 39.60 13.40 54.27 1.00 Non-VX S 22.88 31.56 8.69 35.30 2.34 ~0 8 Protocol II: Four gilts were vaccinated with a 2 ml dose of vaccine A. One gilt failed to farrow because of an infection of porcine parvovirus and was removed from the facility as soon as disease was evident.
Pigs from remaining gilts were challenged with toxin as follows: 9 pigs from one gilt at 10 days old; 2 pigs from a second gilt at 12 days old; and 6 pigs from a third gilt at 4 days old. Gilts from the same herd with farrowing dates similar to vaccinated gilts provided contemporary unvaccinated control pigs.
Vaccinated and unvaccinated control pigs were challenged prior to weaning and thereafter commingled until slaughtered for final scoring. Table III
summarizes the effects of challenge on pigs farrowed by dams which received two doses of vaccine A. The data are presented (a) independently of litter, and (b) by litter averages.
These results show significantly lower snout scores and significantly better weight gains in the vaccinated group. These observations indicate that two doses of vaccine A given to dams induced the production of antitoxin that was passively transferred to otherwise susceptible pigs. Furthermore, the duration of passive protection was at least 10 to 12 days.
Table III
(a) Weight at Weight at Weight Weight Mean Group No. Challenge Slaughter Gain Gain Snout 5 (lb) o Score VX 15 6.87 21.00 14.13 205.83 3.02 Non-VX 5 8.20 16.40 8.20 100.00 3.70 10 (b) vx Gilt 629 7 8.71 21.50 12.79 147.09 3.68 Gilt 639 2 8.00 29.25 21.25 268.65 2.38 Gilt 633 6 4.33 17.67 13.33 310.28 2.46 Gilt Avg 7.02 22.81 15.79 242.01 2.84 Non-VX 5 8.20 16.40 8.20 100.00 3.70 Pig sera and colostrum samples from the experiments of Example 3 were tested for antibodies against the toxin by a kinetic ELISA. Briefly, purified toxin (250 ng/well) in 0.1 M sodium borate, pH 9.1, was adsorbed to flat-bottom 96 well Nunc microtiter plates overnight at 4 C. Plates were then blocked at 37 C for minutes with 10% nonfat dried milk in PBS with 0.05%
Tweeri 20 (blocking buffer). Blocking buffer was rinsed *
from the plates with two PBS/0.05% Tweeri 20 (PBS/Tween) * Trademark rinses, followed by a PBS rinse. Sera were diluted 1:100 in blocking buffer, and 50 l samples were added to each of four wells. Plates were incubated for 60 minutes at 37 C, and then rinsed as above.
Goat-anti swine IgG (heavy and light chain specific)-horseradish peroxidase (Kirkegaard and Perry Laboratories, Gaithersburg, MD] was diluted 1:500 in blocking buffer, and added (50 l) to each well.
Following a 60 minute incubation at 37 C, plates were rinsed as above. ABTS substrate (2,21-axino-di-3-ethyl-benzthiazoline sulfonate) [Kirkegaard and Perry] was added, and plates were read immediately on a Vmax ELISA
reader at 405 nm (Molecular Devices Corporation, Palo Alto, CA]. Each well was read eight times during a one-minute interval, and the rate of the enzymatic reaction was calculated.
Rates were calculated as the change in milli units of optical density (mOD) per minute. Thus a reading of 10o moD per minute would be equal to an OD of 1.0 in 10 minutes. Values were then corrected for the amount of serum used per well and reported as mOD/min/ml of serum. For instance, if 50 l of serum produced a reading of 100 mOD per minute, the reported value would be 2,000 mOD units per minute per ml.
?I
The following controls were included on each ELISA plate. (1) Serum control: each diluted pig serum was placed in a well that did not contain antigen, then exposed to all subsequent reagents to check for non-specific adsorption to the plate. At the dilution of pig sera (1:100) used, no color greater than that obtained in the negative serum control was seen. (2) Negative pig serum control: each plate included three wells of a known negative pig serum diluted 1:100 in blocking buffer. (3) Positive pig serum controls: serum containing specific antibodies to the toxin was diluted in negative pig serum to obtain sera containing high, moderate, and low concentrations of specific antibody.
These three sera were diluted 1:100 in blocking buffer and placed in triplicate on each plate. Background, or non-specific reactivity, was determined in wells that contained all reagents except pig serum.
Table IV below summarizes the ELISA titers of the dams and pigs vaccinated with toxoid vaccines A and B, respectively, according to Protocol II (Example 4).
The table gives the geometric mean titers of sera taken before the first and second dam vaccinations, of the colostrum, and of sera taken before the first and second pig vaccinations, challenge, and slaughter, as compared to unvaccinated controls-(Non-Vx).
Table IV
Geometric Mean ELISA Titers ist 2nd 1st 2nd Dam Dam Pig Pig Group Vx Vx Colostrum Vx Vx Challenge Slaughter VX 21.71 0 173.00 0.99 1.73 109.03 139.07 Non 25.35 12.34 83.38 1.45 1.72 .38 8.64 VX
These results indicate that two doses of vaccine A given to dams, followed by two doses of vaccine B given to their pigs, induced immunity to the toxin in otherwise susceptible pigs.
From the same study (Protocol II, Example 4) Table V summarizes the ELISA titers of vaccinated (vaccine A) and unvaccinated dams and their unvaccinated pigs.
2~~8625-8 Table V
Geometric Mean ELISA Titers lst 2nd Dam Dam A: Group Vx Vx Colostrum Challenge Slaughter Vx 28.19 .76 104.31 7.98 22.53 Non-Vx 27.56 15.53 80.60 .19 .75 Individual ELISA titers Geometric mean titers of litters at:
lst 2nd Dam Dam B: Group Vx Vx Colostrum Challenge Slaughter Vaccinated Gilt 629 21.80 5.80 70.60 1.66 29.15 Gilt 639 29.20 - 18.60 26.07 25.39 Gilt 633 35.20 - 154.10 36.43 16.03 Average 27.73 1.93 81.10 21.39 23.03 Unvaccinated Gilt 636 23.40 10.80 66.80 - 12.40 Gilt 631 30.60 11.90 135.90 - 0.20 Gilt 626 19.80 17.60 76.70 - 9.40 Gilt 635 40.60 20.40 - - -Gilt 632 27.60 19.60 60.60 4.60 -Average 28.40 16.06 68.00 0.92 4.4 Table VI shows a summary of challenge-of-immunity studies for dam and pigs vaccinated with various doses (in relative toxoid units, RU) of free toxoid preparations.
WO 91/19419 PCr/US91/040 2 Table VI
RU Administered to: Significant Protection against Dams Pigs No. Weight Loss Turbinate atrophy 5 876 32 307 70 10 Yes Yes 876 + 32 0 15 Yes Yes 391 52 0 10 No No 0 391 + 52 9 No No 10 The data shows significant protection of pigs farrowed by dams vaccinated with two doses of a vaccine containing 876 32 RU of free toxoid. In pigs or pregnant gilts, two doses of experimental lots containing between 300 and 400 RU/dose, did not appear to induce 15 protection.
COMPOSITION
An embodiment of this composition includes a bacterin-toxoid of P. multocida in which the toxoid has 20 been stabilized within the bacterial cell.
A culture of P. multocida, type D, strain 8, is grown in the following medium: Tryptic Soy Broth without Dextrose (Difco) 30 g; Yeast extract (Difco) 5 g; Dextrose 4 g; Deionized water to 1 liter; pH of 25 approximately 7; sterilized by autoclaving at 121 C.
The culture is aerated with agitation to maintain the dissolved oxygen concentration at approximately 35% of saturation. The temperature is maintained at 37 C, and the pH at 7 by the addition of lON NaOH solution as needed. Towards the end of exponential growth, aeration is discontinued and the culture is inactivated by the addition of formaldehyde solution (USP) to a final concentration of 0.5% v/v. The culture is then held at 37 C for four days. Other inactivating agents, such as beta-propriolactone, glutaraldehyde, and binary ethyleneamine can be used in place of formaldehyde.
A sample is withdrawn to test whether inactivation is complete by administering the sample to guinea pigs. Guinea pigs should be alive and healthy at 7 days after subcutaneous injection with 4 ml volumes of the culture. At this point the toxin within the cells is completely converted to toxoid, which is safe, very stable and capable of inducing the production of neutralizing antitoxins upon injection into animals.
The inactivated culture is centrifuged. The sedimented bacteria are dispensed in sufficient supernatant fluid to make a suspension with an OD of 4.2.
The suspension is then adsorbed with A1(OH)3 gel, 25% v/v, thimerosol (0.01% w/v) is added as a preservative, and the pH is adjusted to 6.5 0.2.
WO 91/19419 PGT/US91/0.4092 ~~ ~bb ~ cl r +vC1 This P. multocida bacterin-toxoid may be used in vaccines as the sole vaccine component.
Alternatively, the bacterin toxoid may be employed in vaccine compositions with other vaccine components.
Whether the bacterin-toxoid is used alone or in combination, saponin (0.5 mg/ml) may be added as adjuvant.
One example of a combination vaccine contains a suspension of adsorbed P. multocida (O.D. 7.5 before adsorption) mixed with equal volumes of similarly adsorbed and preserved cultures of Bordetella bronchiseptica (O.D. 4.2 before adsorption) and Erysipelothrix rhusionathiae (O.D. 7.5 before adsorption). This bacterin-toxoid vaccine, referred to as Atrobac 3 (Beecham Laboratories), has a dose volume of 2 ml.
Combination vaccines may contain the bacterin toxoid of Example 5, and/or the soluble toxoid of Example 1 with optional components, such as other inactivated microorganisms, e.g., B. bronchiseptica and other strains of P. multocida (P. multocida serotype A for protection against pleuritic and pneumonic forms of pasteurellosis).
One exemplary combination vaccine employs the P. multocida bacterin-toxoid described in Example 5 and the P. multocida free toxoid described in Example 1.
Another combination vaccine may include the free toxoid and bacterin toxoid of P. multocida type D, described above, with an inactivated whole culture of B.
bronchiseptica.
Still another efficacious vaccine composition against infection by P. multocida can be prepared by combining the bacterin-toxoid vaccine composition, Atrobac 3, described above in Example 5, and the soluble, free toxoid of P. multocida prepared as described above in Example 1.
One exemplary formulation for a combination vaccine consists of the following components:
Component Vol/ds (ml) Vol (ml) Atrobac 3~ 2.000 250.00 Free toxoid (650 U/ml) 0.242 30.25 oil/lethicin 0.100 12.50 Tween*80 0.056 7.00 Span'80 0.024 3.00 TOTALS* 3.000 375.00 * Trademark c D!t'~~C~~
o~1r~r For emulsification, these components were combined and emulsified, as a single batch, for 2 minutes. For production scale, it is anticipated that metered in-line rather than batch combination is desirable.
Other ingredients may be added to, or may replace existing ingredients in, the specific formulation above. For example, aluminum hydroxide gel may be employed as an adjuvant in place of oil/lethicin.
Another combination vaccine was prepared as follows: E. bronchiseptica, Strain 2-9 NADC [National Animal Disease Center, Ames, Iowa] was subcultured six times. P. multocida type A strain 169 was cultured in a manner similar to that described for strain 8 in Example 1. For example, at the end of their respective growth periods, cultures of B. bronchiseptica and P. multocida type A strain 169 are inactivated by the addition of beta-propiolactone (BPL). A second addition of BPL is made 2 to 18 hours following the first. The final concentration of BPL does not exceed 1:500 (0.2%). Each culture is incubated at less than 20 C with constant agitation for at least 12 hours.
::A 02086258 2000-06-14 For inactivated cultures of B. bronchiseptica and P. multocida type A strain 169, sterile mineral oil [Drakeol] containing 3.3% to 40% by weight of lecithin [Central Soya] is added as adjuvant. In the final 5 product, the concentration of the oil fraction is approximately 5% by volume. Tween*80 is added to a final concentration of between 0.7 and 2.8%. An emulsifier is added to a final concentration of about 0.3 to 1.2%
(e.g., Span 80). A selected paraben, e.g. methyl p-10 hydroxyl-benzoate, propyl p-hydroxylbenzoate, or butyl p-hydroxylbenzoate, may be added as an additional preservative.
The P. multocida free toxoid is mixed with sterile aluminum hydroxide gel (equivalent to 2% A1203) as 15 adjuvant. In the final product the concentration of aluminum hydroxide gel is 12% by volume.
Concentration is performed by ultrafiltration under aseptic conditions.
In an exemplary combination vaccine, the B.
20 bronchiseptica fraction contains at least 1500 nephelometric units per vaccine dose. The nephelometric units are based on the value measured at the time of harvest. The P. multocida type A strain 169 fraction contains at least 3.4 absorbance units per dose. The 25 absorbency units are based on the value measured at the * Trademark WO 91/19419 P(.T/US91/04092 s.~3 time of inactivation. The P. multocida free-toxoid fraction contains at least 450 relative toxoid units per 2.0 ml dose. Relative toxoid units are measured prior to final product assembly.
One or more complete or partial bulk lots of each fraction are combined with adjuvant and saline diluent to obtain the standard antigen concentration.
These fractions are formulated prior to final assembly by combining the B. bronchiseptica and P.
multocida type A strain 169 components (Fraction I), preparing the free toxoid formulation (Fraction II), and combining Fractions I and II (Vaccine) in the proportions shown in Table VII below.
Table VII
Component Vol/2.0 ml Total Vol (ml) dose (ml) FRACTION I:
B. bronchiseptica 0.250 6,250 P. multocida type A 169 0.500 L2,500 Oil/Lethicin 0.100 2,500 Saline 0.150 3,750 Totals 1.000 25,000 FRACTION II:
E. multocida Toxoid 0.300 7,500 A1(OH)3 gel 0.240 6,000 Saline 0.460 11,500 Totals 1.000 25,000 VACCINE:
Fraction I 1.000 25,000 Fraction II 1.000 25,000 Totals 2.000 50,000 The vaccine compositions of Examples 2, 5, 6 and 7 are useful in the prevention of atrophic rhinitis and pneumonia in swine caused by B. bronchiseptica and/or P. multocida. During the vaccine tests, it was surprisingly observed in the evaluation of the antibody response in swine, that combining the P. multocida bacterin-toxoid and free toxoid had more than an additive effect on the induction of antitoxin, compared to use of the bacterin-toxoid alone or the free toxoid alone.
In one experiment, groups of pigs were vaccinated with Atrobac 3; which contains the P.
multocida bacterin-toxoid and preserved cultures of B.
bronchiseptica and E. rhusiopelothrix (Example 5), or with the free soluble P. multocida toxoid of Example 1 only, or with a combination of bacterin-toxoid and soluble toxoid as described in Example 6. Table VIII
demonstrates antibody response to vaccination with free toxoid alone, with bacterin-toxoid alone and with a combination of these two vaccine components. The ELISA
titers indicate a synergistic effect of this combination vaccine. This combination vaccine composition is believed to induce the best immunity in swine.
* Trademark 2 S, The post vaccination sera were also assayed for neutralizing antitoxin, the actual protective antibody, by the method of Roberts and Swearingin, Am. J. Vet.
Res., 49: 2168 (1988). The antitoxin values show a strong synergy of the free and cell-bound toxoids (Table VIII).
Table IX demonstrates the results of another experiment wherein a vaccine containing whole cell inactivated cultures of P. multocida (PmD), soluble toxoid and B. bronchiseptica inactivated whole cells (Bb), was used in guinea pigs and serum antibody levels measured by the EBL tissue culture assay [J.M. Rutteret al, Veterinary Record, 114: 393-396 (1984)]. In this experiment the combination vaccine dosageunit is 2 ml/dose. In this experiment 600 RU toxoid failed to induce an appreciable anti-toxin response. In contrast, 600 RU toxoid combined with inactivated cultures of P.
multocida (PmD) induced an anti-toxin response level of 128. This demonstration serves as yet another example of immunologic synergy for soluble toxoid and inactivated cultures of toxigenic P. multocida.
WO 91/19419 PCT/US91/040.92 Table VIII
Serum Neutralizing No. Bacterin Free Antibody Antitoxin Pigs Toxoid Toxoid Adjuvant Levels units/ml 5 (ml) (RU) PRE POST POST
Vx Vx Vx 8 0 ml 200 A120H3 <10 13 <1 8 0 ml 200 Amphigen-A120H3 <10 16 <1 8 2 ml 0 A120H3 <10 93 20 10 8 2 ml 0 Amphigen-A120H3 <10 46 20 8 2 ml 120 A"0H3 <10 252 40 8 2 ml 120 Ambhigen-A120H3 <10 302 80 Table IX
Bacterin- Free Dose Serum Antibody 15 Toxoid Toxoid Fraction Adjuvant Levels (RU) PRE-Vx POST-Vx Bb+PmD 600 1/25 Amphigen-A120H3 < 2 128 Bb+PmD 300 1/25 Amphigen-A1ZOH3 < 2 4 Bb+PmD 0 1/25 Amphigen-A120H3 < 2 < 2 20 Bb 600 1/25 Amphigen-A120H3 < 2 4 Bb 300 1/25 Amphigen-A120H3 < 2 < 2 A further embodiment of the vaccine 25 co}npositions of this invention includes a combination vaccine containing a B. bronchisebtica bacterin, a P.
multocida toxoid of Example 1, a P. multocida type A
strain 169 bacterin described in Example 7, and an E.
rhusiopathiae bacterin. This vaccine is useful for the 30 vaccination of healthy swine as an aid in prevention of p~ t,c) r=U
41 f~ ") ;3 ~ ~
atrophic rhinitis, erysipelas and pneumonia caused by B.
bronchiseptica, Erysipelothrix rhusiopathiae and P.
multocida.
Cultures of B. bronchiseptica and P. multocida type A strain 169 are inactivated and individually.
formulated into fractions as described in the above example.
Cultures of E. rhusionathiae strain SE-9 (Dellen Labs, Omaha, Nebraska] are inactivated by the addition of formaldehyde solution (37 percent) to a final concentration of 0.35 to 0.45 percent. The E.
rhusiopathiae fraction is formulated in aluminum hydroxide gel as described for the free-toxoid fraction.
The free toxoid is prepared and formulated as described above in Examples 1 and 2.
Concentration is performed by ultrafiltration under aseptic conditions.
Each fraction is combined with adjuvant and saline diluent to obtain.the standard antigen concentration. These fractions are formulated prior to final assembly by combining the B. bronchiseptica and P.
multocida type A strain 169 components (Fraction III), preparing the free toxoid and E. rhusiopathiae components (Fraction IV) and combining Fractions III and IV
(Vaccine) in the proportions shown in the Table X below.
More specifically, the free toxoid of this invention is prepared as follows: A selected toxigenic P. multocida strain is grown in a suitable culture medium. At the end of the growth cycle, the toxin is liberated from the cells by conventional physical or chemical means e.g., french press or sonic disruption, and cellular debris is removed by centrifugation and filtration. The cell-free extracted toxin is then incubated, preferably at pH of about 10.5, at ambient or slightly cooler temperature for preferably 18 hours.
Following this incubation, the pH is adjusted to neutrality. This process results in complete detoxification of the toxin, providing a toxoid soluble in aqueous solutions (e.g. phosphate buffered saline, tris buffered saline).
The soluble P. multocida toxoid preparation of this invention is both antigenic and immunogenic.
Specifically, the soluble toxoid can elicit antibodies that can bind to the toxin, and neutralize its toxicity.
Further, the soluble toxoid of this invention is characteristically stable at 4 C for at least 24 months, which is a highly advantageous commercial characteristic, indicating that this vacc-ine may be stored for later use.
2 :~~~2 5V 8 8 As another embodiment of this invention there is provided a whole bacterin-toxoid of P. multocida which contains the toxoid encapsulated and stabilized within the bacterial cell. The bacterin toxoid is prepared from a culture that is still growing exponentially and that has not yet begun to release the toxin into the growth medium. Formalin (formaldelhyde solution USP) is added at a concentration of 0.5% v/v and inactivation is continued at about 37 C for 4 days. Other formalin concentrations may be employed in this method. However a higher concentration will require a shorter inactivating incubation period, and a lower concentration will require a longer inactivating incubation period. One of $kill in the art can readily determine these parameters based on this disclosure. The toxoid is thereby encapsulated within the bacterial cell. The dead bacterial cells, with the toxoid sequestered safely within, are ideal antigenic particles for presentation to those host cells that mediate the immunizing process. This is especially important for animals that have not previously been exposed to the toxin or the toxoid and that totally lack antitoxin.
In the P. multocida bacterin-toxoid of this invention the cell-bound toxoid is remarkably stable.
Loss of antigenic potency was undetectable after storage at 4 C for more than two years.
9 .~ 1 v For purposes of this invention, any toxigenic strain of P. multocida may be used to provide the free toxoid or the bacterin-toxoid of this invention. The free or cell-bound toxoids described above can be derived from any strain of P. multocida which elaborates dermonecrotic toxin. Several such strains are available, e.g., from the American Type Culture Collection, Rockville, Maryland or from a variety of veterinary colleges or laboratories. The strain used below in the examples is P. multocida, type D, strain 8, which is available, upon request, from the University of Illinois.
Suitable culture media for use in growing the P. multocida cultures may be selected by one of skill in the art, but preferably includes, without limitation, the medium described by Herriott et al, "Defined Medium for Growth of Hemophilus Influenzae", J. Bact., 101:'513-516 (1970).
The above described novel free toxoid and whole bacterin-toxoid may be employed separately in vaccine compositions for induction of an antitoxin response that will prevent the pathological changes characteristic of atrophic rhinitis caused by toxigenic P. multocida. In a vaccine composition, an immunogenic amount of.the free toxoid or the bacterin-toxoid is desirably mixed with -'~ r suitable conventional vaccine adjuvants and physiologic vehicles for injection into mammals, especially swine.
A more preferred vaccine composition is provided by a synergistic combination of the free toxoid 5 and the whole bacterin-toxoid described above. The combination vaccine of this invention combines the whole bacterin-toxoid with the soluble toxoid, both vaccine components prepared as described above. No other toxoids or vaccines are prepared in this manner. Such a 10 combination vaccine is prepared by mixing an immunogenic amount of free toxoid and an immunogenic amount of bacterin-toxoid with suitable adjuvants and physiologic vehicles for injection into mammals. Preferred.adjuvants include amphigen and aluminum hydroxide gel.
In vaccination experiments with animals, as reported below in Examples 8 and 10, these two vaccine components have been found to act synergistically in a single vaccine preparation. The "combination vaccine"
produces in the vaccinated animal a surprisingly greater effect than that expected by simply adding the effects of each toxoid component administered separately. This combination vaccine stimulates a remarkable production of antitoxin in tested animals. This combined effect can also be generated by sequentially administering the bacterin-toxoid vaccine,-followed by an injection of the soluble toxoid vaccine.
2 '13; 8 6 29, 8 While not wishing to be bound by theory, it is presently believed that the bacterin-toxoid vaccine primes the animals, particularly immunologically naive animals incapable of responding to soluble toxoid. A
second dose of the bacterin-bound toxoid induces a moderate secondary response. Once primed by the toxoid-rich cells of the bacterin-toxoid, however, the anima].s are very responsive to the soluble free toxoid. Just as the bacterin-toxoid is a superior priming agent, the soluble toxoid has been observed to be a superior booster.
Still other preferred vaccine compositions of this invention result from combining the free toxoid and/or the bacterin-toxoid of this invention with other vaccinal agents. An illustrative example is a vaccine composition formed by the combination of a whole cell B.
bronchiseptica bacterin with the P. multocida bacterin-toxoid. Alternatively, the P. multocida bacterin-toxoid is illustrated in further combination with E.
rhusionathiae. Other possible vaccinal agents which may be combined with the vaccine components of this invention include, without limitation, Escherichia coli, Streptococcus suis, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Clostridium perfrinaens types C and D toxoids, Pseudorabies Virus Vaccine (modified live virus and/or killed virus), Rotavirus Vaccine (modified live virus), Coronavirus Vaccine (modified live virus).
Vaccines of the invention may be prepared as pharmaceutical compositions containing an effective immunogenic amount of the free toxoid and/or the whole bacterin-toxoid, as active ingredients in a nontoxic and sterile pharmaceutically acceptable carrier. A preferred embodiment of the vaccine of the invention is composed of an aqueous suspension or solution containing the free toxoid and/or bacterin-toxoid, preferably buffered at physiological pH, in a form ready for injection.
Alternatively or additionally, the free toxoid and/or bacterin-toxoid can be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response. Such adjuvants include, among others, amphigen, aluminum hydroxide, muramyl dipeptide, and saponins such as Quil A.
In yet another exemplary alternative, the free toxoid and/or bacterin-toxoid can be administered with another immunostimulating preparation, such as B.
bronchiseptica or E. rhusiopathiae bacterins prepared by known techniques.
* Trademark For purposes of this invention an immunogenic amount of free soluble toxoid, when administered as the sole active ingredient, may be defined in terms of relative toxoid units ("RU"). The value of RU was determined empirically based on an estimate of the amount of toxoid which, when inoculated into mice, would elicit an immune response that protected mice against the lethal effects of intraperitoneal inoculation of approximately 30 LDso of purified toxin. In this system, an antigen extinction study was performed and a PD$o determined. A
PD50, which is a calculated value, is defined as the amount of toxoid required to protect 50 percent of the mice from challenge with a defined amount of toxin, in this instance, 30 LD50 of purified toxin. Thus one RU is approximately equal to one mouse PD50. Thus, a range of immunogenic amounts of free soluble toxoid is between about 50 to about 1000 RU. More preferably the immunogenic amount ranges between about 50 to about 650 RU. Another preferred range is between about 80 to about 450 RU. Still another preferred range is between about 80 to about 150 RU. Another.immunogenic amount of the free toxoid, as defined by weight, ranges between about 16.2 and about 32.4 g toxoid.
WO 91/19419 P('I'/US91/04092 208 16 2r)0 For purposes of this invention an immunogenic amount of bacterin-toxoid, when injected as the sole active ingredient, is defined as an optical density (O.D.) of between about 0.5 and about 8 per ml, more desirably, about 1 to about 4 per ml. Still another preferred range is an O.D. of between 1 to about 3 per ml. As used throughout this specification, the terms O.D., optical unit (OU) or absorbency unit are interchangeable and are measured at 625 nm in a Spectronic 20 spectrophotometer unless otherwise specified.
In a vaccine composition containing both components, the same immunogenic amounts may be employed.
Alternatively, due to the synergy of the components when combined, the immunogenic amount of the free soluble toxoid may range between about 100 and about 150 RU and, more preferably between about 100 to about 120 RU. The immunogenic, amount of the bacterin-toxoid in combination with the free toxoid may be in the lower O.D. ranges, from about 1 to about 3, and more preferably, about 2.
In such a combination vaccine, the bacterin-toxoid may be reduced to approximately 1.875.O.D. or absorbency units.
Other appropriate therapeutically effective doses can be determined readily by those of skill in the art based on the above immunogenic amounts, the condition being treated and the physiological characteristics of the animal. It is preferred that the vaccine of the invention, when in a pharmaceutical preparation, be present in unit dosage forms. Accordingly, a pharmaceutical preparation provides a unit dosage of 5 between 0.5 to 3 mis of a sterile preparation containing an immunogenic amount of the active ingredients, whether the active ingredient is the free toxoid only, the cell-bound bacterin-toxoid only, or a combination thereof. In the presence of additional active agents, these unit 10 dosages can be readily adjusted by those of skill in the art.
The presently preferred formulation, which appears to give maximum synergy is a Bordetella bronchiseptica, Erysipelothrix rhusiopathiae, Pasteurella 15 multocida bacterin toxoid combination which contains approximately 100 RU free toxoid with approximately 1.875 absorbency units cell-bound toxoid.
A desirable dosage regimen involves administration of two doses of desired vaccine composition, where the antigenic content (i.e., immunogenic amount) of each fraction is desirably as stated above. The mode of administration of the vaccines of the invention may be any suitable route which delivers the vapcine to the host. However, the vaccine is preferably administered s-ubcutaneously or by intramuscular injection. Other modes of administration may also be employed, where desired, such as intradermally or intravenously.
Present investigations with swine employ intramuscular injection of two doses of vaccine administered to the subject animal at least two weeks apart. These studies have shown that, for each of the above described vaccine compositions, a primary immunization of newborn animals is desirably initiated at about one week of age with a booster dose at weaning age.
For primary immunization of pregnant dams, two doses are recommended with the last dose administered two weeks before farrowing. A booster dose is recommended prior to each subsequent farrowing. Semi-annual revaccination is recommended for boars.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, general health, sex, and diet of the patient; the species of the patient; the time of administration; the route of administration; synergistic effects with any other drugs being administered; and the degree of protection being sought. Of course, the administration can be repeated at suitable intervals if necessary or desirable.
WO 91/19419 PC'T/US91/04092 ~tl 8 6 2J8 The specific mechanism of protection induced by the vaccine compositions of the present invention is the induction of toxin-neutralizing antibody (antitoxin) in vaccinated animals, as indicated by the in vivo animal tests described below.
The examples which follow illustrate preferred methods for preparing the free soluble toxoid and bacterin-toxoid of the invention and for preparing and testing a variety of vaccines containing these novel components. These examples are illustrative only and do not limit the scope of the present invention.
A. Culturina the P. multocida P. multocida type D (strain 8) [Dr. Ross Cowart, University of Illinois, Urbana, Illinois) is subcultured in a modified chemically defined synthetic medium for one day. The medium is described by Herriott et al, J. Bact., 101:513-516 (1970).
The pH of the assembled medium is adjusted to 7.3 + 0.2 with sterile NaOH. Cells from this culture are transferred to fresh synthetic medium and this culture, when grown, is combined with a cryopreservative and stored at -70 C. Production cultures are grown to harvest during incubation at approximately 36 1 C for WO 91 / 19419 PC'!'/US91 /04092 between 3 and 24 hours following inoculation. The dissolved oxygen content of the culture is maintained by aeration with sterile air and by agitation. Sterile antifoam solution is used to control foam. The pH of the culture is maintained at 7:3 0.2.
At the end of the growth cycle, multocida cultures are examined and cell density is determined by absorbance at 650 nm. Agitation is then decreased, and aeration and pH control are discontinued.
The toxin content of the lysate is measured by mouse lethality (LD50) and by the Enzyme-linked Immunosorbent.Assay (ELISA) described below in Example 4.
B. Pre-detoxification treatment Following growth of the organism, sterile merthiolate is added to the culture in an amount less than or equal to 0.01 percent weight per volume. Culture fluids may be aseptically transferred through closed connections to a sterile closed container. The container is connected through closed fittings to an apparatus used to physically lyse cells and release cellular contents, e.g., a "GAULIN" model l5M laboratory homogenizer.
Bacterial cells in the culture fluid are lysed by continuous passage through the pressure chamber of the homogenizer. This subjects the cells to an immediate pressure drop from between an initial pressure 19 ru (,~vl3i7n~~J
of between 2000 and 5000 psi to ambient pressure of 15 psi. The lysed cells are aseptically deposited into another closed container.
The lysate is clarified by sequential steps of centrifugation and/or microporous filtration.
Clarified solutions may be concentrated before or after filter sterilization. Ethylenediaminetetraacetic acid (EDTA), in an amount up to a final concentration of 5 mM, and glycerol, in an amount up to a final concentration of 1.0% (vol/vol), are added before concentrating and filter-sterilizing, to prevent aggregation of the concentrated proteins.
C. Detoxification Sterile 5 N NaOH is slowly and aseptically added to sterile toxin to increase the pH to approximately 10.55 0.10 pH units. At this pH, the detoxification occurs as the mixture is allowed to stir slowly at approximately 15 1 C for.between 15 and 24 hours. The pH is not adjusted thereafter until detoxification is complete or aliquots are taken to measure residual toxicity. Sterile 5 N HC1 is then slowly and aseptically added to adjust the pH to 6.80 +
0.20 pH units.
WO 91/19419 PCT/US91/0401%2 2 0 8 6>5 8 20 At two-hour intervals beginning 16 hours after the pH is adjusted to 10.55, an aliquot is taken.
Residual toxicity of each aliquot is measured and expressed in mouse LD50's per mL. A preparation with an initial value of nearly 10,000 LDso's per mL is usually detoxified 18 hours after adjusting the pH to 10.55, without appreciable decrease in assayable antigen content. Thereafter the pH is adjusted to 6.80 + 0.1 unit with 5N HC1. The toxoid is then stored at 2 to 7 C
until combined with other components and assembled into vaccine compositions. If the injection of mice shows any residual toxicity, the pH of the preparation is again raised to 10.55, and the temperature to 15 C. After several hours, depending on the degree of toxicity detected, the preparation is neutralized, cooled, stored, and tested once more.
An illustrative toxoid vaccine formulation according to the invention was made by preparing the soluble free toxoid as described above in Example 1.
The buffer used to prepare the vaccine compositions is sterile saline at a neutral pH. Sterile aluminum hydroxide gel is used as adjuvant and added at a level sufficient to adsorb toxoid, generally 12% 1%
(vol/vol). The vaccine compositions are prepared by thoroughly mixing, then dispensing the indicated amount of toxoid and aluminum hydroxide gel into a 500 ml beaker. Sterile saline is then added. This mixture is stirred and stored at 4 C. Dosage amounts of 2 ml/dose are desirable, which provides about 450 relative toxoid units per dose.
Table I illustrates the formulation of two free-toxoid vaccines according to the invention.
Table I
Experimental Lot Component Total Volume A Toxoid Concentrate 150.0 ml Aluminum Hydroxide Gel 36.0 ml Sterile Saline 114.0 ml Total 300.0 ml B Toxoid Concentrate 235.0 ml Aluminum Hydroxide Gel 41.0 ml Sterile Saline 304.0 ml Total 580.0 ml These free-toxoid vaccine formulations are useful as an aid in prevention of atrophic rhinitis in swine caused by P. multocida infections. An exemplary test of the free toxoid vaccine is performed by injecting the formulations into swine (pigs and dams) as described below.
2~~8 6 2 Using the formulations of Example vaccinations were administered intramuscularly to pigs and dams selected at random according to the following protocols. In each test after vaccination the animals were challenged with purified toxin at a dose known to consistently induce clinical signs of atrophic rhinitis in pigs. Toxicity of DNT was evaluated in mice before and after challenge. The total dose of toxin each pig received was 8.4 g, or 50 mouse LD50. Toxin was administered in three equal doses over a three day period beginning approximately two weeks following vaccination.
Results of the challenge were evaluated approximately 28 days following the first dose of toxin.
The percent weight gain was calculated by the number of pounds gained in the 28 days following challenge divided by the weight, in pounds, at challenge. Nasal turbinate atrophy was evaluated by cross-section of the snout at the first premolar tooth as follows: score 0, normal;
score 1, minimal atrophy; score 2, moderate atrophy;
score 3, substantial atrophy; score 4, near complete atrophy; and score 5, complete atrophy.
Protocol I: Four gilts were vaccinated with a 2 ml dose of P. multocida free toxoid (A), described above in Example 2. Two-gilts failed to farrow because of an infection of porcine parvovirus and were removed from the facility as soon as disease was evident. Pigs born of the two remaining gilts were vaccinated at 13 days of age (gilt 637, 7 pigs) and 9 days of age (gilt 638, 4 pigs) with a 2 ml dose of P. multocida free toxoid (B), described in Example 2. Second vaccinations were administered to all pigs two weeks later. Pigs were challenged with a dose of toxin two weeks following the second vaccination. Gilts from the same herd with farrowing dates similar to vaccinated gilts provided contemporary unvaccinated control pigs.
Following challenge, vaccinated and unvaccinated control pigs were commingled until they were slaughtered for final scoring. Table II illustrates the effects of challenge on pigs which were farrowed from dams vaccinated with two doses of vaccine A, and which were themselves vaccinated (VX) with two doses of free toxoid vaccine 5, compared to unvaccinated (NonVX) animals. These results show significantly lower snout scores and significantly better weight gains in the vaccinated group.
Table II
Weight at Weight at Weight Weight Mean Group No. Challenge Slaughter Gain Gain Snout (lb) % Score VX 10 26.20 39.60 13.40 54.27 1.00 Non-VX S 22.88 31.56 8.69 35.30 2.34 ~0 8 Protocol II: Four gilts were vaccinated with a 2 ml dose of vaccine A. One gilt failed to farrow because of an infection of porcine parvovirus and was removed from the facility as soon as disease was evident.
Pigs from remaining gilts were challenged with toxin as follows: 9 pigs from one gilt at 10 days old; 2 pigs from a second gilt at 12 days old; and 6 pigs from a third gilt at 4 days old. Gilts from the same herd with farrowing dates similar to vaccinated gilts provided contemporary unvaccinated control pigs.
Vaccinated and unvaccinated control pigs were challenged prior to weaning and thereafter commingled until slaughtered for final scoring. Table III
summarizes the effects of challenge on pigs farrowed by dams which received two doses of vaccine A. The data are presented (a) independently of litter, and (b) by litter averages.
These results show significantly lower snout scores and significantly better weight gains in the vaccinated group. These observations indicate that two doses of vaccine A given to dams induced the production of antitoxin that was passively transferred to otherwise susceptible pigs. Furthermore, the duration of passive protection was at least 10 to 12 days.
Table III
(a) Weight at Weight at Weight Weight Mean Group No. Challenge Slaughter Gain Gain Snout 5 (lb) o Score VX 15 6.87 21.00 14.13 205.83 3.02 Non-VX 5 8.20 16.40 8.20 100.00 3.70 10 (b) vx Gilt 629 7 8.71 21.50 12.79 147.09 3.68 Gilt 639 2 8.00 29.25 21.25 268.65 2.38 Gilt 633 6 4.33 17.67 13.33 310.28 2.46 Gilt Avg 7.02 22.81 15.79 242.01 2.84 Non-VX 5 8.20 16.40 8.20 100.00 3.70 Pig sera and colostrum samples from the experiments of Example 3 were tested for antibodies against the toxin by a kinetic ELISA. Briefly, purified toxin (250 ng/well) in 0.1 M sodium borate, pH 9.1, was adsorbed to flat-bottom 96 well Nunc microtiter plates overnight at 4 C. Plates were then blocked at 37 C for minutes with 10% nonfat dried milk in PBS with 0.05%
Tweeri 20 (blocking buffer). Blocking buffer was rinsed *
from the plates with two PBS/0.05% Tweeri 20 (PBS/Tween) * Trademark rinses, followed by a PBS rinse. Sera were diluted 1:100 in blocking buffer, and 50 l samples were added to each of four wells. Plates were incubated for 60 minutes at 37 C, and then rinsed as above.
Goat-anti swine IgG (heavy and light chain specific)-horseradish peroxidase (Kirkegaard and Perry Laboratories, Gaithersburg, MD] was diluted 1:500 in blocking buffer, and added (50 l) to each well.
Following a 60 minute incubation at 37 C, plates were rinsed as above. ABTS substrate (2,21-axino-di-3-ethyl-benzthiazoline sulfonate) [Kirkegaard and Perry] was added, and plates were read immediately on a Vmax ELISA
reader at 405 nm (Molecular Devices Corporation, Palo Alto, CA]. Each well was read eight times during a one-minute interval, and the rate of the enzymatic reaction was calculated.
Rates were calculated as the change in milli units of optical density (mOD) per minute. Thus a reading of 10o moD per minute would be equal to an OD of 1.0 in 10 minutes. Values were then corrected for the amount of serum used per well and reported as mOD/min/ml of serum. For instance, if 50 l of serum produced a reading of 100 mOD per minute, the reported value would be 2,000 mOD units per minute per ml.
?I
The following controls were included on each ELISA plate. (1) Serum control: each diluted pig serum was placed in a well that did not contain antigen, then exposed to all subsequent reagents to check for non-specific adsorption to the plate. At the dilution of pig sera (1:100) used, no color greater than that obtained in the negative serum control was seen. (2) Negative pig serum control: each plate included three wells of a known negative pig serum diluted 1:100 in blocking buffer. (3) Positive pig serum controls: serum containing specific antibodies to the toxin was diluted in negative pig serum to obtain sera containing high, moderate, and low concentrations of specific antibody.
These three sera were diluted 1:100 in blocking buffer and placed in triplicate on each plate. Background, or non-specific reactivity, was determined in wells that contained all reagents except pig serum.
Table IV below summarizes the ELISA titers of the dams and pigs vaccinated with toxoid vaccines A and B, respectively, according to Protocol II (Example 4).
The table gives the geometric mean titers of sera taken before the first and second dam vaccinations, of the colostrum, and of sera taken before the first and second pig vaccinations, challenge, and slaughter, as compared to unvaccinated controls-(Non-Vx).
Table IV
Geometric Mean ELISA Titers ist 2nd 1st 2nd Dam Dam Pig Pig Group Vx Vx Colostrum Vx Vx Challenge Slaughter VX 21.71 0 173.00 0.99 1.73 109.03 139.07 Non 25.35 12.34 83.38 1.45 1.72 .38 8.64 VX
These results indicate that two doses of vaccine A given to dams, followed by two doses of vaccine B given to their pigs, induced immunity to the toxin in otherwise susceptible pigs.
From the same study (Protocol II, Example 4) Table V summarizes the ELISA titers of vaccinated (vaccine A) and unvaccinated dams and their unvaccinated pigs.
2~~8625-8 Table V
Geometric Mean ELISA Titers lst 2nd Dam Dam A: Group Vx Vx Colostrum Challenge Slaughter Vx 28.19 .76 104.31 7.98 22.53 Non-Vx 27.56 15.53 80.60 .19 .75 Individual ELISA titers Geometric mean titers of litters at:
lst 2nd Dam Dam B: Group Vx Vx Colostrum Challenge Slaughter Vaccinated Gilt 629 21.80 5.80 70.60 1.66 29.15 Gilt 639 29.20 - 18.60 26.07 25.39 Gilt 633 35.20 - 154.10 36.43 16.03 Average 27.73 1.93 81.10 21.39 23.03 Unvaccinated Gilt 636 23.40 10.80 66.80 - 12.40 Gilt 631 30.60 11.90 135.90 - 0.20 Gilt 626 19.80 17.60 76.70 - 9.40 Gilt 635 40.60 20.40 - - -Gilt 632 27.60 19.60 60.60 4.60 -Average 28.40 16.06 68.00 0.92 4.4 Table VI shows a summary of challenge-of-immunity studies for dam and pigs vaccinated with various doses (in relative toxoid units, RU) of free toxoid preparations.
WO 91/19419 PCr/US91/040 2 Table VI
RU Administered to: Significant Protection against Dams Pigs No. Weight Loss Turbinate atrophy 5 876 32 307 70 10 Yes Yes 876 + 32 0 15 Yes Yes 391 52 0 10 No No 0 391 + 52 9 No No 10 The data shows significant protection of pigs farrowed by dams vaccinated with two doses of a vaccine containing 876 32 RU of free toxoid. In pigs or pregnant gilts, two doses of experimental lots containing between 300 and 400 RU/dose, did not appear to induce 15 protection.
COMPOSITION
An embodiment of this composition includes a bacterin-toxoid of P. multocida in which the toxoid has 20 been stabilized within the bacterial cell.
A culture of P. multocida, type D, strain 8, is grown in the following medium: Tryptic Soy Broth without Dextrose (Difco) 30 g; Yeast extract (Difco) 5 g; Dextrose 4 g; Deionized water to 1 liter; pH of 25 approximately 7; sterilized by autoclaving at 121 C.
The culture is aerated with agitation to maintain the dissolved oxygen concentration at approximately 35% of saturation. The temperature is maintained at 37 C, and the pH at 7 by the addition of lON NaOH solution as needed. Towards the end of exponential growth, aeration is discontinued and the culture is inactivated by the addition of formaldehyde solution (USP) to a final concentration of 0.5% v/v. The culture is then held at 37 C for four days. Other inactivating agents, such as beta-propriolactone, glutaraldehyde, and binary ethyleneamine can be used in place of formaldehyde.
A sample is withdrawn to test whether inactivation is complete by administering the sample to guinea pigs. Guinea pigs should be alive and healthy at 7 days after subcutaneous injection with 4 ml volumes of the culture. At this point the toxin within the cells is completely converted to toxoid, which is safe, very stable and capable of inducing the production of neutralizing antitoxins upon injection into animals.
The inactivated culture is centrifuged. The sedimented bacteria are dispensed in sufficient supernatant fluid to make a suspension with an OD of 4.2.
The suspension is then adsorbed with A1(OH)3 gel, 25% v/v, thimerosol (0.01% w/v) is added as a preservative, and the pH is adjusted to 6.5 0.2.
WO 91/19419 PGT/US91/0.4092 ~~ ~bb ~ cl r +vC1 This P. multocida bacterin-toxoid may be used in vaccines as the sole vaccine component.
Alternatively, the bacterin toxoid may be employed in vaccine compositions with other vaccine components.
Whether the bacterin-toxoid is used alone or in combination, saponin (0.5 mg/ml) may be added as adjuvant.
One example of a combination vaccine contains a suspension of adsorbed P. multocida (O.D. 7.5 before adsorption) mixed with equal volumes of similarly adsorbed and preserved cultures of Bordetella bronchiseptica (O.D. 4.2 before adsorption) and Erysipelothrix rhusionathiae (O.D. 7.5 before adsorption). This bacterin-toxoid vaccine, referred to as Atrobac 3 (Beecham Laboratories), has a dose volume of 2 ml.
Combination vaccines may contain the bacterin toxoid of Example 5, and/or the soluble toxoid of Example 1 with optional components, such as other inactivated microorganisms, e.g., B. bronchiseptica and other strains of P. multocida (P. multocida serotype A for protection against pleuritic and pneumonic forms of pasteurellosis).
One exemplary combination vaccine employs the P. multocida bacterin-toxoid described in Example 5 and the P. multocida free toxoid described in Example 1.
Another combination vaccine may include the free toxoid and bacterin toxoid of P. multocida type D, described above, with an inactivated whole culture of B.
bronchiseptica.
Still another efficacious vaccine composition against infection by P. multocida can be prepared by combining the bacterin-toxoid vaccine composition, Atrobac 3, described above in Example 5, and the soluble, free toxoid of P. multocida prepared as described above in Example 1.
One exemplary formulation for a combination vaccine consists of the following components:
Component Vol/ds (ml) Vol (ml) Atrobac 3~ 2.000 250.00 Free toxoid (650 U/ml) 0.242 30.25 oil/lethicin 0.100 12.50 Tween*80 0.056 7.00 Span'80 0.024 3.00 TOTALS* 3.000 375.00 * Trademark c D!t'~~C~~
o~1r~r For emulsification, these components were combined and emulsified, as a single batch, for 2 minutes. For production scale, it is anticipated that metered in-line rather than batch combination is desirable.
Other ingredients may be added to, or may replace existing ingredients in, the specific formulation above. For example, aluminum hydroxide gel may be employed as an adjuvant in place of oil/lethicin.
Another combination vaccine was prepared as follows: E. bronchiseptica, Strain 2-9 NADC [National Animal Disease Center, Ames, Iowa] was subcultured six times. P. multocida type A strain 169 was cultured in a manner similar to that described for strain 8 in Example 1. For example, at the end of their respective growth periods, cultures of B. bronchiseptica and P. multocida type A strain 169 are inactivated by the addition of beta-propiolactone (BPL). A second addition of BPL is made 2 to 18 hours following the first. The final concentration of BPL does not exceed 1:500 (0.2%). Each culture is incubated at less than 20 C with constant agitation for at least 12 hours.
::A 02086258 2000-06-14 For inactivated cultures of B. bronchiseptica and P. multocida type A strain 169, sterile mineral oil [Drakeol] containing 3.3% to 40% by weight of lecithin [Central Soya] is added as adjuvant. In the final 5 product, the concentration of the oil fraction is approximately 5% by volume. Tween*80 is added to a final concentration of between 0.7 and 2.8%. An emulsifier is added to a final concentration of about 0.3 to 1.2%
(e.g., Span 80). A selected paraben, e.g. methyl p-10 hydroxyl-benzoate, propyl p-hydroxylbenzoate, or butyl p-hydroxylbenzoate, may be added as an additional preservative.
The P. multocida free toxoid is mixed with sterile aluminum hydroxide gel (equivalent to 2% A1203) as 15 adjuvant. In the final product the concentration of aluminum hydroxide gel is 12% by volume.
Concentration is performed by ultrafiltration under aseptic conditions.
In an exemplary combination vaccine, the B.
20 bronchiseptica fraction contains at least 1500 nephelometric units per vaccine dose. The nephelometric units are based on the value measured at the time of harvest. The P. multocida type A strain 169 fraction contains at least 3.4 absorbance units per dose. The 25 absorbency units are based on the value measured at the * Trademark WO 91/19419 P(.T/US91/04092 s.~3 time of inactivation. The P. multocida free-toxoid fraction contains at least 450 relative toxoid units per 2.0 ml dose. Relative toxoid units are measured prior to final product assembly.
One or more complete or partial bulk lots of each fraction are combined with adjuvant and saline diluent to obtain the standard antigen concentration.
These fractions are formulated prior to final assembly by combining the B. bronchiseptica and P.
multocida type A strain 169 components (Fraction I), preparing the free toxoid formulation (Fraction II), and combining Fractions I and II (Vaccine) in the proportions shown in Table VII below.
Table VII
Component Vol/2.0 ml Total Vol (ml) dose (ml) FRACTION I:
B. bronchiseptica 0.250 6,250 P. multocida type A 169 0.500 L2,500 Oil/Lethicin 0.100 2,500 Saline 0.150 3,750 Totals 1.000 25,000 FRACTION II:
E. multocida Toxoid 0.300 7,500 A1(OH)3 gel 0.240 6,000 Saline 0.460 11,500 Totals 1.000 25,000 VACCINE:
Fraction I 1.000 25,000 Fraction II 1.000 25,000 Totals 2.000 50,000 The vaccine compositions of Examples 2, 5, 6 and 7 are useful in the prevention of atrophic rhinitis and pneumonia in swine caused by B. bronchiseptica and/or P. multocida. During the vaccine tests, it was surprisingly observed in the evaluation of the antibody response in swine, that combining the P. multocida bacterin-toxoid and free toxoid had more than an additive effect on the induction of antitoxin, compared to use of the bacterin-toxoid alone or the free toxoid alone.
In one experiment, groups of pigs were vaccinated with Atrobac 3; which contains the P.
multocida bacterin-toxoid and preserved cultures of B.
bronchiseptica and E. rhusiopelothrix (Example 5), or with the free soluble P. multocida toxoid of Example 1 only, or with a combination of bacterin-toxoid and soluble toxoid as described in Example 6. Table VIII
demonstrates antibody response to vaccination with free toxoid alone, with bacterin-toxoid alone and with a combination of these two vaccine components. The ELISA
titers indicate a synergistic effect of this combination vaccine. This combination vaccine composition is believed to induce the best immunity in swine.
* Trademark 2 S, The post vaccination sera were also assayed for neutralizing antitoxin, the actual protective antibody, by the method of Roberts and Swearingin, Am. J. Vet.
Res., 49: 2168 (1988). The antitoxin values show a strong synergy of the free and cell-bound toxoids (Table VIII).
Table IX demonstrates the results of another experiment wherein a vaccine containing whole cell inactivated cultures of P. multocida (PmD), soluble toxoid and B. bronchiseptica inactivated whole cells (Bb), was used in guinea pigs and serum antibody levels measured by the EBL tissue culture assay [J.M. Rutteret al, Veterinary Record, 114: 393-396 (1984)]. In this experiment the combination vaccine dosageunit is 2 ml/dose. In this experiment 600 RU toxoid failed to induce an appreciable anti-toxin response. In contrast, 600 RU toxoid combined with inactivated cultures of P.
multocida (PmD) induced an anti-toxin response level of 128. This demonstration serves as yet another example of immunologic synergy for soluble toxoid and inactivated cultures of toxigenic P. multocida.
WO 91/19419 PCT/US91/040.92 Table VIII
Serum Neutralizing No. Bacterin Free Antibody Antitoxin Pigs Toxoid Toxoid Adjuvant Levels units/ml 5 (ml) (RU) PRE POST POST
Vx Vx Vx 8 0 ml 200 A120H3 <10 13 <1 8 0 ml 200 Amphigen-A120H3 <10 16 <1 8 2 ml 0 A120H3 <10 93 20 10 8 2 ml 0 Amphigen-A120H3 <10 46 20 8 2 ml 120 A"0H3 <10 252 40 8 2 ml 120 Ambhigen-A120H3 <10 302 80 Table IX
Bacterin- Free Dose Serum Antibody 15 Toxoid Toxoid Fraction Adjuvant Levels (RU) PRE-Vx POST-Vx Bb+PmD 600 1/25 Amphigen-A120H3 < 2 128 Bb+PmD 300 1/25 Amphigen-A1ZOH3 < 2 4 Bb+PmD 0 1/25 Amphigen-A120H3 < 2 < 2 20 Bb 600 1/25 Amphigen-A120H3 < 2 4 Bb 300 1/25 Amphigen-A120H3 < 2 < 2 A further embodiment of the vaccine 25 co}npositions of this invention includes a combination vaccine containing a B. bronchisebtica bacterin, a P.
multocida toxoid of Example 1, a P. multocida type A
strain 169 bacterin described in Example 7, and an E.
rhusiopathiae bacterin. This vaccine is useful for the 30 vaccination of healthy swine as an aid in prevention of p~ t,c) r=U
41 f~ ") ;3 ~ ~
atrophic rhinitis, erysipelas and pneumonia caused by B.
bronchiseptica, Erysipelothrix rhusiopathiae and P.
multocida.
Cultures of B. bronchiseptica and P. multocida type A strain 169 are inactivated and individually.
formulated into fractions as described in the above example.
Cultures of E. rhusionathiae strain SE-9 (Dellen Labs, Omaha, Nebraska] are inactivated by the addition of formaldehyde solution (37 percent) to a final concentration of 0.35 to 0.45 percent. The E.
rhusiopathiae fraction is formulated in aluminum hydroxide gel as described for the free-toxoid fraction.
The free toxoid is prepared and formulated as described above in Examples 1 and 2.
Concentration is performed by ultrafiltration under aseptic conditions.
Each fraction is combined with adjuvant and saline diluent to obtain.the standard antigen concentration. These fractions are formulated prior to final assembly by combining the B. bronchiseptica and P.
multocida type A strain 169 components (Fraction III), preparing the free toxoid and E. rhusiopathiae components (Fraction IV) and combining Fractions III and IV
(Vaccine) in the proportions shown in the Table X below.
Table X
Component Vol/3.0 ml Total Vol (ml) dose (ml) FRACTION III:
B. bronchisebtica 0.250 6,250 P.. multocida type A 169 0.500 12,500 Oil/Lethicin 0.100 2,500 Saline 0.150 3,750 Totals 1.000 25,000 FRACTION IV:
rhusiogathiae 0.500 12,500 ~. multocida 8 Toxoid 0.300 7,500 aluminum hydroxide gel 0.600 15,000 Saline 0.600 15,000 Totals 2.000 50,000 VACCINE:
Fraction III 1.000 25,000 Fraction IV 2.000 50,000 Totals 3.000 75,000 WO 91/19419 PCI'/US91/04092 Each dose of vaccine contains at least 1500 nephelometric units of B. bronchiseptica, at least 3.0 absorbency units of E. rhusiopathiae, at least 3.4 absorbance units at 650 nm of P. multocida type A strain 169, and at least 450 relative units of P. multocida toxoid. The absorbency units are based on the value measured at the time of harvest.
Five experimental vaccines according to the present invention were evaluated for efficacy in animal studies using pathogenic challenge of vaccinated and unvaccinated animals. The experimental vaccines are formulated essentially as described above and include the following active components as set out in Table XI below:
Table XI
P. multocida B. bronchi- Strain E. rhusio-VX septica 169 Toxoid pathiae C 170 mis 425 mls 646 mls 0 !2C)c4)(' 44 N ..r :.) 'at 1+i t =.~
I. P. multocida type A Challenge One experiment was conducted as follows: On day 1 and day 14, ten pigs were vaccinated with a 2 ml dose of Vaccine C and ten pigs with a 2 ml dose of Vaccine D. Two weeks after the second inoculation, these pigs and ten contemporary unvaccinated controls were infected with P. multocida strain 169. Disease severity was quantified by a clinical score at death or two,weeks after infection (Table XII).
Table XII
Clinical Scores VX No. Dead/Total Mean S.D. Signif.
C 10 1/10 4.0 2.75 p<.0025 D 10 5/10 9.0 1.41 none NonVx 10 5/10 8.4 2.31 CONTROL
Tab1e XIII summarizes the agglutinin responses (geometric mean titer (GMT)) of the three groups to P.
multocida, at firstand second vaccinations, at challenge, and at death or slaughter.
WO 91/19419 PCf/US91/04092 Table XIII
AGGLUTININ TITERS (GM) At Death or VX 1st Vaccine 2nd Vaccine At Challenge Slaughter C <4 16 138 939 D <4 <4 <4 36 NonVX <4 <4 <4 128 Following challenge, clinical signs in susceptible pigs were consistently severe. Predominant clinical signs included death (or moribundity), lameness, and pleuritis and pericarditis with fibrinous deposits and adhesions. These signs were abundant in all pigs except those vaccinated with Vaccine C. Of the ten pigs given Vaccine C, substantial protection was evident in nine. Based on these observations, two doses of Vaccine C given to susceptible pigs induced immunity to challenge with P. multocida type A.
II. Toxin Challenge Another experiment was performed as follows:
On day 1 and day 15, five pregnant dams were vaccinated with Vaccine D (2 ml dose) and five with Vaccine E (2 ml dose). Farrowings occurred beginning about two weeks thereafter. Five pigs from each of the ten vaccinated dams and five pigs from unvaccinated dams were given a 2 E)~~N ~c) 46 2 ml dose of Vaccine E. At weaning, vaccinated pigs and unvaccinated pigs (littermates to vaccinated pigs farrowed from unvaccinated dams) were challenged with toxin. About one month thereafter, pigs were scored for clinical signs of atrophic rhinitis.
A summary of weight gains and snout scores for each group is shown in Table XIV below.
Table XIV
Group Mean Values Number Wt. (lbs.) at: Wt Gain by: Snout Group Dams Pigs Chal. Final (lbs) % Score 1 5 25 21.32 59.04 37.72 179.11 1.13 35 2 5 25 19.96 57.48 37.52 191.80 1.02 3 5 25 **21.76 51.62 29.67 138.97 2.83 ***21.76 43.72 21.96 99.95 4 5 10 **21.20 52.43 31.00 144.91 2.57 ***21.20 36.70 21.70 101.44 5 4 4 23.50 64.75 41.25 176.58 0.44 Group 1: Vaccinated: Dams - vaccine D; Pigs - vaccine E
Group 2: Vaccinated: Dams - vaccine E; Pigs - vaccine E
Group 3: Vaccinated: Dams - None; Pigs - vaccine E
Group 4: Unvaccinated: Dams and Pigs Group 5: Sentinel * Pigs in groups 3, 4, and 5 were farrowed from common dams ** Values calculated using only pigs surviving challenge *** Values calculated including pigs not surviving challenge ~
Pigs in groups 1 and 2 (Table XIII) gained 37.72 and 37.52 pounds per litter, or 179.11 and 191.80 percent, respectively. Susceptible pigs, groups 3 and 4, gained 29.67 and 31.00 pounds, or 138.97 and 144.91 percent, respectively. The difference in weight gains for susceptible pigs (groups 3 and 4, n=35) were compared to weight gains for vaccinated and protected pigs (groups 1 and 2, n=50) by student "t" test. The difference was very highly significant (p <<0.0005) showing increased weight gain for groups 1 and 2 (Table XIII). The snout scores for susceptible pigs (groups 3 and 4) were compared to those for pigs in groups 1 and 2. There was a marked decrease in the destruction of nasal turbinates in groups 1 and 2. The difference was highly significant (Student "t" test: p <0.0005). According to the analysis of weight gains and nasal turbinate scores, pigs in groups 1 and 2 were protected from challenge with toxin (Table XIV).
Serum samples were collected immediately prior to each dam and pig vaccination, from the dam at farrowing, from pigs when challenged with,toxin (chal), and from pigs when signs of AR were scored (slaughter).
Table XV summarizes the antibody titers of the dams and pigs in the various treatment groups. N/A means the data are not available.
WO 91/19419 pCi'/US91/04092 s {_' ~.) f 4~ () (t;~=ac?
2 s~
Table XV
Geometric Mean Titer (GMT) to each fraction for sera taken at or before:
1st 2nd 1st 2nd Dam Dam Pig Pig Group Vx Vx Farrow Colostrum Vx Vx Chal Slaughter Bb 21.11 294.06 147.03 776.05 25.64 19.97 22.05 7.16 PmA 16.00 18.38 10.56 10.56 <4 6.53 82.14 105.40 PmD 9.58 11.33 30.48 195.14 18.95 11.94 61.36 248.53 Bb 24.25 512.00 222.85 1552.00 28.65 17.88 14.72 18.38 PmA 16.00 73.52 73.52 168.90 32.90 13.93 65.80 75.59 PmD 6.13 9.99 32.36 245.14 28.56 16.49 106.02 272.76 Bb N/A N/A 9.19 42.22 5.90 7.78 17.67 14,.32 PmA N/A N/A 8.00 12.13 <4 8.69 91.77 100.43 PmD N/A N/A 7.56 12.48 5.03 5.06 5.88 24.60 Bb N/A N/A 9.19 42.22 5.28 4.67 4.29 4.88 PmA N/A N/A 8.00 12.13 <4 4.30 5.15 <4.00 PmD N/A N/A 7.56 12.48. 3.04 3.46 4.34 3.67 Bb N/A N/A 8.00 38.05 13.45 8.00 5.66 4.76 PmA N/A N/A 8.00 12.13 11.32 6.73 5.66 <4.00 PmD N/A N/A 7.56 12.48 - 2.73 4.19 4.40 1.67 For purposes of Table XV, the symbol Bb means B.
bronchiseptica; PmA means P. multocida type A (strain 169) and PmD means P. mu].tocida toxin. The vaccine groups are as defined in Table XIV.
These results show that two doses of Vaccine E did not induce antibody to toxin when given to pigs farrowed from unvaccinated dams. These pigs remained susceptible to challenge with toxin. In contrast, two doses of Vaccine E
induced antibody to toxin in pigs farrowed from vaccinated dams. From these data, vaccination of dams and pigs with toxoid immunized pigs against the toxin of P. multocida.
III. Challenge with E. rhusiopathiae Still an additional experiment was performed as follows: On day 1 and day 14, eight pigs each were vaccinated with vaccines F and G (see Table XI). On the same dates eight pigs were vaccinated with two doses of vaccine E. On day 1 four pigs were vaccinated with a single dose of erysipelothrix bacterin. On about day 30, pigs were challenged with virulent E. rhusionathiae.
A summary of response to challenge is presented in Table XVI below.
t,50 Table XVI
Number Vaccine Normal Total Percent Result F 8 8 100 3Sat G 7 8 87.5 3Sat 'Exp. ER 4 4 100 3Sat ZE 2 8 25 'Sat Vaccinated: single.dose of an experimental Erysipelothrix rhusiopathiae bacterin. Pigs in this group served as a positive control.
2 Vaccinated: 2 doses vaccine E (no erysipelothrix). Pigs in this group served as susceptible controls for challenge with virulent E. rhusiogathiae and for comparison of serologic response to unchallenged fractions.
3 Satisfactory protection of vaccinated animals as defined in 9 CFR 113.04(e).
Satisfactory disease in susceptible swine, e.g., unvaccinated controls as defined in same regulation.
The results in Table XVI show that at least 75% of the susceptible animals displayed clinical signs of erysipelas, validating the challenge. At least 75% of the animals vaccinated with two doses of vaccines F or G were without clinical signs of erysipelas. These results indicate that two doses of vaccines F or G provide effective protection against challenge with virulent E. rhusiopathiae.
At the end of the observation period, all surviving pigs were treated with penicillin for 4 to 5 days at 1,000 units per pound. Once signs of erysipelas were no longer apparent, all pigs were challenged with P. multocida toxin.
A summary of mean weight gains and snout scores for each group is shown in Table XVII below.
Table XVII
Challenge Final Wt Gain'in: Snout Vaccine Number Wt Wt' (lbs) Score F 8 52.25 72.13 19.88 38.04 1.63 G 8 51.50 78.25 26.75 52.13 1.31 *Exp. ER 4 43.75 63.75 20.00 45.75 2.50 ~*~- i~k R4.lq 61.91 1-1 . 4Z. 40 .14 -z . o0 Pigs in this group served as susceptible controls for aha2lenqe with DN'T.
** Protection not expected (see Tabie xva), Based on the results in Tables XIV and XV, two doses of vaccine E (Table XI) were not predicted to induce a protective immune response to challenge with DNT. However, two doses of vaccine E were adequate to prime susceptible pigs since a secondary response to toxin was evident WO 91/19419 PCr/US91/04092 -~, c ~a ,1~ Q
cs '52 following toxin challenge (Table XVIII). Similarly, pigs vaccinated with the two vaccines ER and E did not respond as well as pigs farrowed and nursing from vaccinated dams (Table XV). However, all pigs vaccinated with vaccines F
and G demonstrated a primary response to vaccination and a secondary response to toxin injection equal or superior to the group vaccinated with vaccine E. Further, pigs given vaccine E were very nearly protected from challenge. These data indicate a freedom from immunological interference between the fractions in experimental vaccines.
Serum samples were collected immediately prior to each vaccination, when E. rhusiopathiae challenge was administered (Erh Chal) when toxin challenge was given (PmD
Chal), and at slaughter. A summary of the serological responses to fractions other than rhusiopathiae is presented in Table XVIII below.
Table XVIII
Geometric Mean Titer (GMT) to each fraction for sera taken at or before:
1st Pig 2nd Pig Erh. PmD
Group* Vx Vx Chal. Chal. Slaughter Bb** 5.19 16.00 47.61 40.03 26.25 PmA <4.00 8.72 256.00 166.00 172.57 PmD 1.33 7.63 26.19 20.10 468.71 Bb 6.87 16.00 36.71 34.90 34.90 PmA <4.00 29.34 139.58 107.63 128.00 PmD 0.66 4.77 23.30 35.70 512.63 Bb <4.00 4.00 4.00 <4.00 4.00 PmA <4.00 42.22 <4.00 8.00 <4.00 PmD 4.96 4.19 4.75 5.67 4.21 Bb 6.17 14.67 49.35 32.00 26.25 PmA 5.18 26.91 139.58 256.00 186.61 PmD 6.86 8.12 6.90 9.04 47.11 Group 6: Vaccinated, vaccine F (see Table XI) Group 7: Vaccinated, vaccine G (see Table XI) Group 8: Vaccinated, Ervsipelothrix rhusiopathiae bacterin vaccine Group 9: Vaccinated, vaccine E (see Table XI) WO 91/19419 PCr/US91/04092 Pigs farrowed by unvaccinated dams and vaccinated with Bordetella bronchiseptica-Pasteurella multocida bacterin-toxoid experimental Vaccine E were protected against challenge with E. multocida type A (strain 169).
From this result it can be concluded that dam vaccination with this formulation is not required in protecting pigs against type A.
Experimental Bordetella bronchiseptica-Erysipelothrix rhusiopathiae-Pasteurella multocida bacterin-toxoid given to susceptible pigs protected at least 75%
against a valid challenge with virulent E. rhusiopathiae.
From this result it is concluded that two doses of this bacterin-toxoid formulated as either a 3 ml dose or a 2 ml dose induced effective immunity against erysipelas.
Example 11 - Combination Vaccine Pigs were immunized in two, 2 mL doses with a combination vaccine according to the invention containing Bordetella bronchiseptica, Ervsipelothrix rhusiopathiae, Pasteurella multocida Bacterin-Toxoid and P. multocida free toxoid, which has been standardized to contain approximately 100 RU free soluble toxoid and 1.875 absorbency units (AU) of cell-bound toxoid.
WO 91/19419 PC'T/US91/04092 The individual components of the vaccine were prepared as described in the preceding Examples. A 2 mL
dose was formulated as follows. The Bordetella bacterin containing 4.13 doses (6195 NU) per mL was adjusted to pH
5 6.5. Al(OH)3 gel (23.85 mL) and 0.615 mL thimerosal, 2.5%
v/v, with EDTA, 2.5% v/v, were added to 930 mL of the Bordetella. The mixture was again adjusted to pH 6.5 and was gently mixed 1 hour at approximately 25 C on a shaker.
Sufficient saline (581.9 mL) was added to make a final 10 volume of 1536.4 mL.
The Erysipelothrix, containing 4.7 opacity units (optical density x volume in ml) per ml, as determined on Spectronic 20D at 625 nm was clarified by centrifuging at 8000 g for 30 minutes. 1800 mL of the supernatant was L5 concentrated by ultrafiltration with a 10,000 MW membrane to a calculated equivalent of 12.5 opacity units per ml to give a final volume of 677 mL. Next 222 mL A1(OH)3 gel and 3.55 mL thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added to 666 mL of concentrated supernatant. The mixture was 20 adjusted to pH 6.6 and gently mixed for 1 hour at appromately 25 C on a shaker.
c'~g~,.t.,"pr ~J
P. multocida type A (2518 mL) which was BPL-inactivated and contained 5.4 opacity units (OU) per mL
(Spectronic 70 at 650 nm), was centrifuged (4500 g for 1 hour) and the cells resuspended in supernatant fluid to 400 mL. Saline (800 mL) was added to obtain a calculated 11.33 opacity units per mL. Al(OH)3 gel (400 mL) and 6.4 mL
thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added. The mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately 25 C on a shaker.
P. multocida Type D strain 4677 [SmithKline Beecham) Cell-Bound Toxoid (3304 mL) containing 2.1 OU per mL (Spectronic 70 at 625 nm) was centrifuged (4500 g for 1 hour), and the cells were resuspended in supernatant fluid to 222 mL. Saline (333 mL) was added to obtain a calculated 12.5 OU per mL. Al(OH)3 gel (185 mL) and 2.96 mL
thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added. The mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately 25 C on a shaker.
For P. multocida Type D, strain 8, free toxoid, 250 mL Al(OH)3 gel and 4.0 mL thimerosal (2.5% v/v) with EDTA (17.5% v/v) were added to 750 mL P. multocida toxoid containing 540 relative units (RU) per mL. This mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately C on a shaker.
A 2 mL dose contains the following amounts of the components prepared as described in the above paragraph: 0.4 mL of the Bordetella bacterin, 0.8 mL culture-clarified Erysipelothrix, 0.4 mL P. multocida type A, 0.2 mL P.
multocida type D cell-bound toxoid, 0.2 mL P. multocida type D free toxoid. This dose was used in the following challenge experiments.
Briefly described, following immunization, pigs were challenged for immunity to E. rhusionathiae in accordance with 9 C.F.R. 113.104e or against atrophic rhinitis by sequential infection with virulent B.
bronchiseptica and P. multocida according to the method of Kobish and Pennings, Vet. Rec., 124:57-61 (1989).
The results of these challenge studies demonstrated that the magnitude of the response to this formulation was greater than an additive effect of combining the gs multocida free toxoid and bacterin-toxoid and represented immunological synergy. In addition, the solid protection induced against a severe challenge with erysipelothrix showed that the removal of bacteria from the E. rhusiopathiae fraction had no adverse effect on the efficacy of this fraction.
, .~
A. Challenae for Immunity to E. rhusiopathiae Twenty-eight crossbread feeder pigs acquired from Sands, Inc. were used to evaluate the effectiveness of decreased antigen levels on immunity of Bordetella brochisei3tica-Ervsipelothrix rhusiopathiae-Pasteurella multocida Bacterin Toxoid. Three groups of eight pigs (treatment groups A, B and C, respectively) were injected intramuscularly in the left side of the neck on day 0 with 2 mL of either a Full Dose, 1/2 Dose, or 1/10 Dose of the above-described vaccine. The one half and one tenth dosages were made by diluting the above formulation with sterile PBS. On day 21, the pigs in treatment groups A, B and C
received a second intramuscular injection of their respective treatment. With the second injection, the injection sites were rotated to the right side of the neck.
On day 39, all pigs, treatment Groups A, B, C and control group D, were challenged with E. rhusiopathiae via a 2 mL
intramuscular injection in the ham.
One animal in the group which received 1/10 dose died for reasons unrelated to vaccination or challenge and was removed from the test. One hundred percent of the non-vaccinated animals displayed characteristic clinical signs or erysipelas and 75% died. In contrast, 100% of the pigs which received a full dose of vaccine were protected. From this data it was concluded that vaccination with the vaccine WO 91/19419 pCT/US91/04092 of this example induced an immunity that withstood a very strong challenge with virulent E. rhusiopathiae.
B. Challenge of Immunity for Atrophic Rhinitis Six of eight naive crossbred late gestation sows (Eberly Farms, Bradshaw, NE) were inoculated intramuscularly approximately 3 and 5 weeks prior to farrowing on two occasions with 2.0 mL of the vaccine formulation described above. At farrowing, pigs in each litter were randomly assigned to treatment groups. Treatment group A received two, 2.0 mL intramuscular injections of the vaccine formulation. The first injection was administered in the left side of the neck when the pigs were one week old and the second was administered in the right side of the neck at weaning age. Treatment group B did not receive any test substance. The pigs born of the two control sows served as control pigs.
At four days of age, the pigs were intranasally challenged with 1.0 mL of B. bronchiseptica (strain 2-9, 2 x 10$ organisms/mL) and again intranasally challengedwith 1.0 mL of P. multocida type D (strain 4677, 8 x 109 organisms/mL) at nine days of age. Five weeks after infection with P. multocida type D, the pigs were slaughtered and nasal turbinate atrophy measured.
~cl si60 The non-vaccinated groups gained significantly less weight than pigs in groups which included vaccination treatment. Further, damage to nasal scrolls was uniformly severe in non-vaccinated pigs farrowed from non-vaccinated dams. In contrast, pigs born to vaccinated dams gained weight at a rate expected of a healthy pig and had significantly less turbinate atrophy. The results of the challenge are summar'ized in Table XIX below in which Group A
represents vaccinated dams, vaccinated pigs; Group B
represents vaccinated dams, non-vaccinted pigs, and Group C
represents non-vaccinated dams, non-vaccinated pigs.
Table XIX
#/Group Weight(lbs) Avg. Signif- Snout Signif Gp Dams Pigs initial Final Dai1v Gain icance Score icance A 5 19 5.25 28.21 0.608 p<0.001 1.97 p<0.001 B 5 19 5.61 31.66 0.688 p<0.001 1.88 p<0.001 C 2 23 5.47 22.50 0.431 control 4.21 control The serological response showed that measurable antibodies to B. bronchisevtica, P. multocida type A, and P. multocida DNT were present in colostrum samples from vaccinated dams and not in colostrum samples from non-vaccinated dams. Further, assay of antibody to these fractions in serum taken from pigs at five days of age (Bordetella challenge) showed transfer of maternal antibody.
~D~~r~
,,.3(:)LaY,C) Table XX below shows antibody titers that were protective against severe atrophic rhinitis caused by B. bronchiseptica and P. multocida infections, regardless of whether immunization was active or passive. In nonvaccinated pigs farrowed from vaccinated dams, however, the results clearly indicate that maternal antibody does not persist and that vaccination of pigs is required for an immunity that endures through the first few months of life.
Table XX
Geometric Mean Titer (GMT) for sera taken at or before:
Dams Pias Dams Borde- Pasteur-ist 2nd tella ella Final Fraction Vx Vx Colostrum Challenge Challenge Bleeding Vaccinated Dams Vacciriated Pigs Bb 7.0 64.0 222.9 7.7 4.8 8.6 PmA 1.4 2.2 249.0 29.4 21.4 5.6 PmD 20.3 43.8 122.5 35.5 19.7 49.7 Non-Vaccinated Pigs Bb 17.2 8.6 4.3 PmA 35.3 22.3 1.8 PmD 46.8 34.2 3.8 Non-vaccinated Dams Non-vaccinated Pigs Bb 11.3 NA < 4 < 4 < 4 < 4 PmA 1.0 NA 19.0 < 4 < 4 < 4 PmD 14.4 NA 16.1 2.8 1.3 0.9 Bb = Bordetella bronchisentica PmA = Pasteurella multocida type A
PmD = Pasteurella multocida DNT
c L ~
~~.
Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. For example, use of other appropriate inactivated pathogens, other than those of B. bronchiseptica and E. rhusiopathiae, may be employed in the combined vaccines of this invention. Similarly, other conventional adjuvants and inactive vaccine components may be employed in the formulations and selected by one of skill in the art.
The dosages and administration protocols for use of these vaccine compositions may also be adjusted by one of skill in the art based on the animal to be vaccinated, the disease for which protection is desired and other related factors.
Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.
Component Vol/3.0 ml Total Vol (ml) dose (ml) FRACTION III:
B. bronchisebtica 0.250 6,250 P.. multocida type A 169 0.500 12,500 Oil/Lethicin 0.100 2,500 Saline 0.150 3,750 Totals 1.000 25,000 FRACTION IV:
rhusiogathiae 0.500 12,500 ~. multocida 8 Toxoid 0.300 7,500 aluminum hydroxide gel 0.600 15,000 Saline 0.600 15,000 Totals 2.000 50,000 VACCINE:
Fraction III 1.000 25,000 Fraction IV 2.000 50,000 Totals 3.000 75,000 WO 91/19419 PCI'/US91/04092 Each dose of vaccine contains at least 1500 nephelometric units of B. bronchiseptica, at least 3.0 absorbency units of E. rhusiopathiae, at least 3.4 absorbance units at 650 nm of P. multocida type A strain 169, and at least 450 relative units of P. multocida toxoid. The absorbency units are based on the value measured at the time of harvest.
Five experimental vaccines according to the present invention were evaluated for efficacy in animal studies using pathogenic challenge of vaccinated and unvaccinated animals. The experimental vaccines are formulated essentially as described above and include the following active components as set out in Table XI below:
Table XI
P. multocida B. bronchi- Strain E. rhusio-VX septica 169 Toxoid pathiae C 170 mis 425 mls 646 mls 0 !2C)c4)(' 44 N ..r :.) 'at 1+i t =.~
I. P. multocida type A Challenge One experiment was conducted as follows: On day 1 and day 14, ten pigs were vaccinated with a 2 ml dose of Vaccine C and ten pigs with a 2 ml dose of Vaccine D. Two weeks after the second inoculation, these pigs and ten contemporary unvaccinated controls were infected with P. multocida strain 169. Disease severity was quantified by a clinical score at death or two,weeks after infection (Table XII).
Table XII
Clinical Scores VX No. Dead/Total Mean S.D. Signif.
C 10 1/10 4.0 2.75 p<.0025 D 10 5/10 9.0 1.41 none NonVx 10 5/10 8.4 2.31 CONTROL
Tab1e XIII summarizes the agglutinin responses (geometric mean titer (GMT)) of the three groups to P.
multocida, at firstand second vaccinations, at challenge, and at death or slaughter.
WO 91/19419 PCf/US91/04092 Table XIII
AGGLUTININ TITERS (GM) At Death or VX 1st Vaccine 2nd Vaccine At Challenge Slaughter C <4 16 138 939 D <4 <4 <4 36 NonVX <4 <4 <4 128 Following challenge, clinical signs in susceptible pigs were consistently severe. Predominant clinical signs included death (or moribundity), lameness, and pleuritis and pericarditis with fibrinous deposits and adhesions. These signs were abundant in all pigs except those vaccinated with Vaccine C. Of the ten pigs given Vaccine C, substantial protection was evident in nine. Based on these observations, two doses of Vaccine C given to susceptible pigs induced immunity to challenge with P. multocida type A.
II. Toxin Challenge Another experiment was performed as follows:
On day 1 and day 15, five pregnant dams were vaccinated with Vaccine D (2 ml dose) and five with Vaccine E (2 ml dose). Farrowings occurred beginning about two weeks thereafter. Five pigs from each of the ten vaccinated dams and five pigs from unvaccinated dams were given a 2 E)~~N ~c) 46 2 ml dose of Vaccine E. At weaning, vaccinated pigs and unvaccinated pigs (littermates to vaccinated pigs farrowed from unvaccinated dams) were challenged with toxin. About one month thereafter, pigs were scored for clinical signs of atrophic rhinitis.
A summary of weight gains and snout scores for each group is shown in Table XIV below.
Table XIV
Group Mean Values Number Wt. (lbs.) at: Wt Gain by: Snout Group Dams Pigs Chal. Final (lbs) % Score 1 5 25 21.32 59.04 37.72 179.11 1.13 35 2 5 25 19.96 57.48 37.52 191.80 1.02 3 5 25 **21.76 51.62 29.67 138.97 2.83 ***21.76 43.72 21.96 99.95 4 5 10 **21.20 52.43 31.00 144.91 2.57 ***21.20 36.70 21.70 101.44 5 4 4 23.50 64.75 41.25 176.58 0.44 Group 1: Vaccinated: Dams - vaccine D; Pigs - vaccine E
Group 2: Vaccinated: Dams - vaccine E; Pigs - vaccine E
Group 3: Vaccinated: Dams - None; Pigs - vaccine E
Group 4: Unvaccinated: Dams and Pigs Group 5: Sentinel * Pigs in groups 3, 4, and 5 were farrowed from common dams ** Values calculated using only pigs surviving challenge *** Values calculated including pigs not surviving challenge ~
Pigs in groups 1 and 2 (Table XIII) gained 37.72 and 37.52 pounds per litter, or 179.11 and 191.80 percent, respectively. Susceptible pigs, groups 3 and 4, gained 29.67 and 31.00 pounds, or 138.97 and 144.91 percent, respectively. The difference in weight gains for susceptible pigs (groups 3 and 4, n=35) were compared to weight gains for vaccinated and protected pigs (groups 1 and 2, n=50) by student "t" test. The difference was very highly significant (p <<0.0005) showing increased weight gain for groups 1 and 2 (Table XIII). The snout scores for susceptible pigs (groups 3 and 4) were compared to those for pigs in groups 1 and 2. There was a marked decrease in the destruction of nasal turbinates in groups 1 and 2. The difference was highly significant (Student "t" test: p <0.0005). According to the analysis of weight gains and nasal turbinate scores, pigs in groups 1 and 2 were protected from challenge with toxin (Table XIV).
Serum samples were collected immediately prior to each dam and pig vaccination, from the dam at farrowing, from pigs when challenged with,toxin (chal), and from pigs when signs of AR were scored (slaughter).
Table XV summarizes the antibody titers of the dams and pigs in the various treatment groups. N/A means the data are not available.
WO 91/19419 pCi'/US91/04092 s {_' ~.) f 4~ () (t;~=ac?
2 s~
Table XV
Geometric Mean Titer (GMT) to each fraction for sera taken at or before:
1st 2nd 1st 2nd Dam Dam Pig Pig Group Vx Vx Farrow Colostrum Vx Vx Chal Slaughter Bb 21.11 294.06 147.03 776.05 25.64 19.97 22.05 7.16 PmA 16.00 18.38 10.56 10.56 <4 6.53 82.14 105.40 PmD 9.58 11.33 30.48 195.14 18.95 11.94 61.36 248.53 Bb 24.25 512.00 222.85 1552.00 28.65 17.88 14.72 18.38 PmA 16.00 73.52 73.52 168.90 32.90 13.93 65.80 75.59 PmD 6.13 9.99 32.36 245.14 28.56 16.49 106.02 272.76 Bb N/A N/A 9.19 42.22 5.90 7.78 17.67 14,.32 PmA N/A N/A 8.00 12.13 <4 8.69 91.77 100.43 PmD N/A N/A 7.56 12.48 5.03 5.06 5.88 24.60 Bb N/A N/A 9.19 42.22 5.28 4.67 4.29 4.88 PmA N/A N/A 8.00 12.13 <4 4.30 5.15 <4.00 PmD N/A N/A 7.56 12.48. 3.04 3.46 4.34 3.67 Bb N/A N/A 8.00 38.05 13.45 8.00 5.66 4.76 PmA N/A N/A 8.00 12.13 11.32 6.73 5.66 <4.00 PmD N/A N/A 7.56 12.48 - 2.73 4.19 4.40 1.67 For purposes of Table XV, the symbol Bb means B.
bronchiseptica; PmA means P. multocida type A (strain 169) and PmD means P. mu].tocida toxin. The vaccine groups are as defined in Table XIV.
These results show that two doses of Vaccine E did not induce antibody to toxin when given to pigs farrowed from unvaccinated dams. These pigs remained susceptible to challenge with toxin. In contrast, two doses of Vaccine E
induced antibody to toxin in pigs farrowed from vaccinated dams. From these data, vaccination of dams and pigs with toxoid immunized pigs against the toxin of P. multocida.
III. Challenge with E. rhusiopathiae Still an additional experiment was performed as follows: On day 1 and day 14, eight pigs each were vaccinated with vaccines F and G (see Table XI). On the same dates eight pigs were vaccinated with two doses of vaccine E. On day 1 four pigs were vaccinated with a single dose of erysipelothrix bacterin. On about day 30, pigs were challenged with virulent E. rhusionathiae.
A summary of response to challenge is presented in Table XVI below.
t,50 Table XVI
Number Vaccine Normal Total Percent Result F 8 8 100 3Sat G 7 8 87.5 3Sat 'Exp. ER 4 4 100 3Sat ZE 2 8 25 'Sat Vaccinated: single.dose of an experimental Erysipelothrix rhusiopathiae bacterin. Pigs in this group served as a positive control.
2 Vaccinated: 2 doses vaccine E (no erysipelothrix). Pigs in this group served as susceptible controls for challenge with virulent E. rhusiogathiae and for comparison of serologic response to unchallenged fractions.
3 Satisfactory protection of vaccinated animals as defined in 9 CFR 113.04(e).
Satisfactory disease in susceptible swine, e.g., unvaccinated controls as defined in same regulation.
The results in Table XVI show that at least 75% of the susceptible animals displayed clinical signs of erysipelas, validating the challenge. At least 75% of the animals vaccinated with two doses of vaccines F or G were without clinical signs of erysipelas. These results indicate that two doses of vaccines F or G provide effective protection against challenge with virulent E. rhusiopathiae.
At the end of the observation period, all surviving pigs were treated with penicillin for 4 to 5 days at 1,000 units per pound. Once signs of erysipelas were no longer apparent, all pigs were challenged with P. multocida toxin.
A summary of mean weight gains and snout scores for each group is shown in Table XVII below.
Table XVII
Challenge Final Wt Gain'in: Snout Vaccine Number Wt Wt' (lbs) Score F 8 52.25 72.13 19.88 38.04 1.63 G 8 51.50 78.25 26.75 52.13 1.31 *Exp. ER 4 43.75 63.75 20.00 45.75 2.50 ~*~- i~k R4.lq 61.91 1-1 . 4Z. 40 .14 -z . o0 Pigs in this group served as susceptible controls for aha2lenqe with DN'T.
** Protection not expected (see Tabie xva), Based on the results in Tables XIV and XV, two doses of vaccine E (Table XI) were not predicted to induce a protective immune response to challenge with DNT. However, two doses of vaccine E were adequate to prime susceptible pigs since a secondary response to toxin was evident WO 91/19419 PCr/US91/04092 -~, c ~a ,1~ Q
cs '52 following toxin challenge (Table XVIII). Similarly, pigs vaccinated with the two vaccines ER and E did not respond as well as pigs farrowed and nursing from vaccinated dams (Table XV). However, all pigs vaccinated with vaccines F
and G demonstrated a primary response to vaccination and a secondary response to toxin injection equal or superior to the group vaccinated with vaccine E. Further, pigs given vaccine E were very nearly protected from challenge. These data indicate a freedom from immunological interference between the fractions in experimental vaccines.
Serum samples were collected immediately prior to each vaccination, when E. rhusiopathiae challenge was administered (Erh Chal) when toxin challenge was given (PmD
Chal), and at slaughter. A summary of the serological responses to fractions other than rhusiopathiae is presented in Table XVIII below.
Table XVIII
Geometric Mean Titer (GMT) to each fraction for sera taken at or before:
1st Pig 2nd Pig Erh. PmD
Group* Vx Vx Chal. Chal. Slaughter Bb** 5.19 16.00 47.61 40.03 26.25 PmA <4.00 8.72 256.00 166.00 172.57 PmD 1.33 7.63 26.19 20.10 468.71 Bb 6.87 16.00 36.71 34.90 34.90 PmA <4.00 29.34 139.58 107.63 128.00 PmD 0.66 4.77 23.30 35.70 512.63 Bb <4.00 4.00 4.00 <4.00 4.00 PmA <4.00 42.22 <4.00 8.00 <4.00 PmD 4.96 4.19 4.75 5.67 4.21 Bb 6.17 14.67 49.35 32.00 26.25 PmA 5.18 26.91 139.58 256.00 186.61 PmD 6.86 8.12 6.90 9.04 47.11 Group 6: Vaccinated, vaccine F (see Table XI) Group 7: Vaccinated, vaccine G (see Table XI) Group 8: Vaccinated, Ervsipelothrix rhusiopathiae bacterin vaccine Group 9: Vaccinated, vaccine E (see Table XI) WO 91/19419 PCr/US91/04092 Pigs farrowed by unvaccinated dams and vaccinated with Bordetella bronchiseptica-Pasteurella multocida bacterin-toxoid experimental Vaccine E were protected against challenge with E. multocida type A (strain 169).
From this result it can be concluded that dam vaccination with this formulation is not required in protecting pigs against type A.
Experimental Bordetella bronchiseptica-Erysipelothrix rhusiopathiae-Pasteurella multocida bacterin-toxoid given to susceptible pigs protected at least 75%
against a valid challenge with virulent E. rhusiopathiae.
From this result it is concluded that two doses of this bacterin-toxoid formulated as either a 3 ml dose or a 2 ml dose induced effective immunity against erysipelas.
Example 11 - Combination Vaccine Pigs were immunized in two, 2 mL doses with a combination vaccine according to the invention containing Bordetella bronchiseptica, Ervsipelothrix rhusiopathiae, Pasteurella multocida Bacterin-Toxoid and P. multocida free toxoid, which has been standardized to contain approximately 100 RU free soluble toxoid and 1.875 absorbency units (AU) of cell-bound toxoid.
WO 91/19419 PC'T/US91/04092 The individual components of the vaccine were prepared as described in the preceding Examples. A 2 mL
dose was formulated as follows. The Bordetella bacterin containing 4.13 doses (6195 NU) per mL was adjusted to pH
5 6.5. Al(OH)3 gel (23.85 mL) and 0.615 mL thimerosal, 2.5%
v/v, with EDTA, 2.5% v/v, were added to 930 mL of the Bordetella. The mixture was again adjusted to pH 6.5 and was gently mixed 1 hour at approximately 25 C on a shaker.
Sufficient saline (581.9 mL) was added to make a final 10 volume of 1536.4 mL.
The Erysipelothrix, containing 4.7 opacity units (optical density x volume in ml) per ml, as determined on Spectronic 20D at 625 nm was clarified by centrifuging at 8000 g for 30 minutes. 1800 mL of the supernatant was L5 concentrated by ultrafiltration with a 10,000 MW membrane to a calculated equivalent of 12.5 opacity units per ml to give a final volume of 677 mL. Next 222 mL A1(OH)3 gel and 3.55 mL thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added to 666 mL of concentrated supernatant. The mixture was 20 adjusted to pH 6.6 and gently mixed for 1 hour at appromately 25 C on a shaker.
c'~g~,.t.,"pr ~J
P. multocida type A (2518 mL) which was BPL-inactivated and contained 5.4 opacity units (OU) per mL
(Spectronic 70 at 650 nm), was centrifuged (4500 g for 1 hour) and the cells resuspended in supernatant fluid to 400 mL. Saline (800 mL) was added to obtain a calculated 11.33 opacity units per mL. Al(OH)3 gel (400 mL) and 6.4 mL
thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added. The mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately 25 C on a shaker.
P. multocida Type D strain 4677 [SmithKline Beecham) Cell-Bound Toxoid (3304 mL) containing 2.1 OU per mL (Spectronic 70 at 625 nm) was centrifuged (4500 g for 1 hour), and the cells were resuspended in supernatant fluid to 222 mL. Saline (333 mL) was added to obtain a calculated 12.5 OU per mL. Al(OH)3 gel (185 mL) and 2.96 mL
thimerosal, 2.5% v/v, with EDTA, 17.5% v/v, were added. The mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately 25 C on a shaker.
For P. multocida Type D, strain 8, free toxoid, 250 mL Al(OH)3 gel and 4.0 mL thimerosal (2.5% v/v) with EDTA (17.5% v/v) were added to 750 mL P. multocida toxoid containing 540 relative units (RU) per mL. This mixture was adjusted to pH 6.5 and gently mixed 1 hour at approximately C on a shaker.
A 2 mL dose contains the following amounts of the components prepared as described in the above paragraph: 0.4 mL of the Bordetella bacterin, 0.8 mL culture-clarified Erysipelothrix, 0.4 mL P. multocida type A, 0.2 mL P.
multocida type D cell-bound toxoid, 0.2 mL P. multocida type D free toxoid. This dose was used in the following challenge experiments.
Briefly described, following immunization, pigs were challenged for immunity to E. rhusionathiae in accordance with 9 C.F.R. 113.104e or against atrophic rhinitis by sequential infection with virulent B.
bronchiseptica and P. multocida according to the method of Kobish and Pennings, Vet. Rec., 124:57-61 (1989).
The results of these challenge studies demonstrated that the magnitude of the response to this formulation was greater than an additive effect of combining the gs multocida free toxoid and bacterin-toxoid and represented immunological synergy. In addition, the solid protection induced against a severe challenge with erysipelothrix showed that the removal of bacteria from the E. rhusiopathiae fraction had no adverse effect on the efficacy of this fraction.
, .~
A. Challenae for Immunity to E. rhusiopathiae Twenty-eight crossbread feeder pigs acquired from Sands, Inc. were used to evaluate the effectiveness of decreased antigen levels on immunity of Bordetella brochisei3tica-Ervsipelothrix rhusiopathiae-Pasteurella multocida Bacterin Toxoid. Three groups of eight pigs (treatment groups A, B and C, respectively) were injected intramuscularly in the left side of the neck on day 0 with 2 mL of either a Full Dose, 1/2 Dose, or 1/10 Dose of the above-described vaccine. The one half and one tenth dosages were made by diluting the above formulation with sterile PBS. On day 21, the pigs in treatment groups A, B and C
received a second intramuscular injection of their respective treatment. With the second injection, the injection sites were rotated to the right side of the neck.
On day 39, all pigs, treatment Groups A, B, C and control group D, were challenged with E. rhusiopathiae via a 2 mL
intramuscular injection in the ham.
One animal in the group which received 1/10 dose died for reasons unrelated to vaccination or challenge and was removed from the test. One hundred percent of the non-vaccinated animals displayed characteristic clinical signs or erysipelas and 75% died. In contrast, 100% of the pigs which received a full dose of vaccine were protected. From this data it was concluded that vaccination with the vaccine WO 91/19419 pCT/US91/04092 of this example induced an immunity that withstood a very strong challenge with virulent E. rhusiopathiae.
B. Challenge of Immunity for Atrophic Rhinitis Six of eight naive crossbred late gestation sows (Eberly Farms, Bradshaw, NE) were inoculated intramuscularly approximately 3 and 5 weeks prior to farrowing on two occasions with 2.0 mL of the vaccine formulation described above. At farrowing, pigs in each litter were randomly assigned to treatment groups. Treatment group A received two, 2.0 mL intramuscular injections of the vaccine formulation. The first injection was administered in the left side of the neck when the pigs were one week old and the second was administered in the right side of the neck at weaning age. Treatment group B did not receive any test substance. The pigs born of the two control sows served as control pigs.
At four days of age, the pigs were intranasally challenged with 1.0 mL of B. bronchiseptica (strain 2-9, 2 x 10$ organisms/mL) and again intranasally challengedwith 1.0 mL of P. multocida type D (strain 4677, 8 x 109 organisms/mL) at nine days of age. Five weeks after infection with P. multocida type D, the pigs were slaughtered and nasal turbinate atrophy measured.
~cl si60 The non-vaccinated groups gained significantly less weight than pigs in groups which included vaccination treatment. Further, damage to nasal scrolls was uniformly severe in non-vaccinated pigs farrowed from non-vaccinated dams. In contrast, pigs born to vaccinated dams gained weight at a rate expected of a healthy pig and had significantly less turbinate atrophy. The results of the challenge are summar'ized in Table XIX below in which Group A
represents vaccinated dams, vaccinated pigs; Group B
represents vaccinated dams, non-vaccinted pigs, and Group C
represents non-vaccinated dams, non-vaccinated pigs.
Table XIX
#/Group Weight(lbs) Avg. Signif- Snout Signif Gp Dams Pigs initial Final Dai1v Gain icance Score icance A 5 19 5.25 28.21 0.608 p<0.001 1.97 p<0.001 B 5 19 5.61 31.66 0.688 p<0.001 1.88 p<0.001 C 2 23 5.47 22.50 0.431 control 4.21 control The serological response showed that measurable antibodies to B. bronchisevtica, P. multocida type A, and P. multocida DNT were present in colostrum samples from vaccinated dams and not in colostrum samples from non-vaccinated dams. Further, assay of antibody to these fractions in serum taken from pigs at five days of age (Bordetella challenge) showed transfer of maternal antibody.
~D~~r~
,,.3(:)LaY,C) Table XX below shows antibody titers that were protective against severe atrophic rhinitis caused by B. bronchiseptica and P. multocida infections, regardless of whether immunization was active or passive. In nonvaccinated pigs farrowed from vaccinated dams, however, the results clearly indicate that maternal antibody does not persist and that vaccination of pigs is required for an immunity that endures through the first few months of life.
Table XX
Geometric Mean Titer (GMT) for sera taken at or before:
Dams Pias Dams Borde- Pasteur-ist 2nd tella ella Final Fraction Vx Vx Colostrum Challenge Challenge Bleeding Vaccinated Dams Vacciriated Pigs Bb 7.0 64.0 222.9 7.7 4.8 8.6 PmA 1.4 2.2 249.0 29.4 21.4 5.6 PmD 20.3 43.8 122.5 35.5 19.7 49.7 Non-Vaccinated Pigs Bb 17.2 8.6 4.3 PmA 35.3 22.3 1.8 PmD 46.8 34.2 3.8 Non-vaccinated Dams Non-vaccinated Pigs Bb 11.3 NA < 4 < 4 < 4 < 4 PmA 1.0 NA 19.0 < 4 < 4 < 4 PmD 14.4 NA 16.1 2.8 1.3 0.9 Bb = Bordetella bronchisentica PmA = Pasteurella multocida type A
PmD = Pasteurella multocida DNT
c L ~
~~.
Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. For example, use of other appropriate inactivated pathogens, other than those of B. bronchiseptica and E. rhusiopathiae, may be employed in the combined vaccines of this invention. Similarly, other conventional adjuvants and inactive vaccine components may be employed in the formulations and selected by one of skill in the art.
The dosages and administration protocols for use of these vaccine compositions may also be adjusted by one of skill in the art based on the animal to be vaccinated, the disease for which protection is desired and other related factors.
Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.
Claims (17)
1. A vaccine composition comprising an immunogenic amount of a toxoid prepared by incubating a cell-free dermonecrotic toxin from Pasteurella multocida under conditions of pH greater than 9; an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid derived from a cell-bound dermonecrotic toxin; and a pharmaceutically acceptable carrier.
2. The vaccine composition according to claim 1, in which the toxoid prepared from the cell-free toxin is prepared by incubating the cell-free toxin under conditions of pH of about 10.5.
3. A vaccine composition comprising an immunogenic amount of a toxoid prepared by incubating a clarified lysate of Pasteurella multocida whole cells under conditions of pH greater than 9; an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid wherein said bacterin is prepared by inactivating a culture of Pasteurella multocida in exponential growth phase; and a pharmaceutically acceptable carrier.
4. The vaccine composition according to any one of claims 1-3, which comprises between 100 and 150 relative toxoid units per ml.
5. The vaccine composition according to any of claims 1 to 3, in which the bacterin is prepared by treating toxin-containing cells from a culture of Pasteurella multocida in the exponential growth phase with formaldehyde in a concentration sufficient to inactivate the cells and to convert the toxin to a cell-bound toxoid.
6. The vaccine composition according to claim 5 in which the Pasteurella multocida bacterin comprising the cell-bound toxoid is prepared by treating cells from the culture with a final concentration of 0.5% v/v formaldehyde.
7. The vaccine composition according to claim 5 or 6, wherein the culture of Pasteurella multocida cells is selected from a toxigenic Type D strain.
8. The vaccine composition according to claims 1 to 7, which exhibits an optical density at 625 nm of between 1 and 3.
9. The vaccine composition according to any of claims 1 to 8, which further comprises an immunogenic amount of one or more additional antigens.
10. The vaccine composition according to claim 9, wherein the additional antigens are selected from the group consisting of a Bordetella bronchiseptica antigen, and Erysipelothrix rhusiopathiae antigen, a Mycoplasma hyopneumoniae antigen, and an Escherichia coli antigen.
11. The vaccine composition according to any of claims 1 to 10, further comprising one or more adjuvants.
12. Use of the vaccine composition of any of claims I to 11 in the manufacture of a medicament for internal use in an animal to protect the animal against Pasteurella multocida.
13. Use of a first vaccine composition comprising an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid derived from a cell-bound dermonecrotic toxin, and a pharmaceutically acceptable carrier in the manufacture of a first medicament, and a second vaccine composition comprising a toxoid prepared by incubating a cell-free dermonecrotic toxin from Pasteurella multocida under conditions of pH greater than 9, and a pharmaceutically acceptable carrier, in the manufacture of a second medicament, which first and second medicaments are intended for internal use in an animal to protect the animal against Pasteurella multocida and which first and second medicament are intended to be sequentially used in the animal.
14. Use of a first vaccine composition comprising an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid wherein said bacterin is prepared by inactivating a culture of Pasteurella multocida in exponential growth phase, and a pharmaceutically acceptable carrier in the manufacture of a first medicament, and a second vaccine composition comprising a toxoid prepared by incubating a clarified lysate of Pasteurella multocida whole cells under conditions of pH greater than 9, and a pharmaceutically acceptable carrier, in the manufacture of a second medicament, which first and second medicaments are intended for internal use in an animal to protect the animal against Pasteurella multocida and which first and second medicament are intended to be sequentially used in the animal.
15. Use of the vaccine composition of any of claims 1-11 for internal use in an animal to protect the animal against Pasteurella multocida.
16. Use of a first vaccine composition comprising an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid derived from a cell-bound dermonecrotic toxin, and a pharmaceutically acceptable carrier, and a second vaccine composition comprising a toxoid prepared by incubating a cell-free dermonecrotic toxin from Pasteurella multocida under conditions of pH greater than 9, and a pharmaceutically acceptable carrier, which first and second vaccines are intended for internal use in an animal to protect the animal against Pasteurella multocida and which said first and second vaccines are intended to be sequentially used in the animal.
17. Use of a first vaccine composition comprising an immunogenic amount of a Pasteurella multocida bacterin comprising a cell-bound toxoid wherein said bacterin is prepared by inactivating a culture of Pasteurella multocida in exponential growth phase, and a pharmaceutically acceptable carrier, and a second vaccine composition comprising a toxoid prepared by incubating a clarified lysate of Pasteurella multocida whole cells under conditions of pH greater than 9, and a pharmaceutically acceptable carrier, which first and second vaccines are intended for internal use in an animal to protect the animal against Pasteurella multocida and which said first and second vaccines are intended to be sequentially used in the animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002312296A CA2312296C (en) | 1990-06-13 | 1991-06-10 | Pasteurella multocida toxoid vaccines |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53745490A | 1990-06-13 | 1990-06-13 | |
US537,454 | 1990-06-13 | ||
PCT/US1991/004092 WO1991019419A1 (en) | 1990-06-13 | 1991-06-10 | Pasteurella multocida toxoid vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002312296A Division CA2312296C (en) | 1990-06-13 | 1991-06-10 | Pasteurella multocida toxoid vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2086258A1 CA2086258A1 (en) | 1991-12-14 |
CA2086258C true CA2086258C (en) | 2007-10-23 |
Family
ID=38650016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002086258A Expired - Lifetime CA2086258C (en) | 1990-06-13 | 1991-06-10 | Pasteurella multocida toxoid vaccines |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2086258C (en) |
-
1991
- 1991-06-10 CA CA002086258A patent/CA2086258C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2086258A1 (en) | 1991-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU657907B2 (en) | Mycoplasma hyopneumoniae vaccine | |
KR101056622B1 (en) | Improved combination vaccine against Mycoplasma hyopneumoniae and swine virus | |
KR100874119B1 (en) | Improved mycoplasma hyopneumoniae bacterin vaccine | |
RU2194752C2 (en) | Strain and culture of strain streptococcus equi tw 928 for horse vaccination | |
US20090263427A1 (en) | Vaccines for mycoplasma bovis and methods of use | |
SK288010B6 (en) | Use of Mycoplasma hyopneumoniae for the manufacture of a medicament | |
EP0651609B1 (en) | Pasteurella multocida toxoid vaccines | |
EP0669971B1 (en) | Method of producing gram-negative bacterial vaccines | |
US20060251674A1 (en) | Formulations and process for production of Bordetella bronchiseptica P68 antigen and vaccines | |
US6022728A (en) | Method for producing a bacterial vaccine and novel vaccines produced thereby | |
US5695769A (en) | Pasteurella multocida toxoid vaccines | |
CA2086258C (en) | Pasteurella multocida toxoid vaccines | |
CA2312296C (en) | Pasteurella multocida toxoid vaccines | |
EP4117721A1 (en) | A vaccine for protection against streptococcus suis serotype 9, sequence type 16 | |
AU669681B2 (en) | Pasteurella multocida toxoid vaccines | |
US11154605B2 (en) | Vaccine comprising Clostridium toxoids | |
WO2023011812A1 (en) | A vaccine for protection against streptococcus suis of various serotypes | |
AU2012207016B2 (en) | Immunogenic compositions comprising Lawsonia intracellularis | |
JPH06503351A (en) | Immunity enhancement of vaccines, especially porcine pleuropneumonia vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |